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Foreword 
 
The evaluation of research and doctoral training is being carried out in the years 2010–2012 and will end in 
2012. The steering group appointed by the Rector in January 2010 set the conditions for participating in 
the evaluation and prepared the Terms of Reference to present the evaluation procedure and criteria. The 
publications and other scientific activities included in the evaluation covered the years 2005–2010. 
The participating unit in the evaluation was defined as a Researcher Community (RC). To obtain a 
critical mass with university-level impact, the number of members was set to range from 20 to 120. The 
RCs were required to contain researchers in all stages of their research career, from doctoral students to 
principal investigators (PIs). All in all, 136 Researcher Communities participated in this voluntary 
evaluation, 5857 persons in total, of whom 1131 were principal investigators. PIs were allowed to 
participate in two communities in certain cases, and 72 of them used this opportunity and participated in 
two RCs. 
This evaluation enabled researchers to define RCs from the “bottom up” and across disciplines. The aim 
of the evaluation was not to assess individual performance but a community with shared aims and 
researcher-training activities. The RCs were able to choose among five different categories that 
characterised the status and main aims of their research. The steering group considered the process of 
applying to participate in the evaluation to be important, which lead to the establishment of these 
categories. In addition, providing a service for the RCs to enable them to benchmark their research at the 
global level was a main goal of the evaluation. 
The data for the evaluation consisted of the RCs’ answers to evaluation questions on supplied e-forms 
and a compilation extracted from the TUHAT – Research Information System (RIS) on 12 April 2011. The 
compilation covered scientific and other publications as well as certain areas of scientific activities. During 
the process, the RCs were asked to check the list of publications and other scientific activities and make 
corrections if needed. These TUHAT compilations are public and available on the evaluation project sites 
of each RC in the TUHAT-RIS. 
In addition to the e-form and TUHAT compilation, University of Leiden (CWTS) carried out bibliometric 
analyses from the articles included in the Web of Science (WoS). This was done on University and RC 
levels. In cases where the publication forums of the RC were clearly not represented by the WoS data, the 
Library of the University of Helsinki conducted a separate analysis of the publications. This was done for 
66 RCs representing the humanities and social sciences. 
The evaluation office also carried out an enquiry targeted to the supervisors and PhD candidates about 
the organisation of doctoral studies at the University of Helsinki. This and other documents describing the 
University and the Finnish higher education system were provided to the panellists. 
The panel feedback for each RC is unique and presented as an entity. The first collective evaluation 
reports available for the whole panel were prepared in July–August 2011. The reports were accessible to all 
panel members via the electronic evaluation platform in August. Scoring from 1 to 5 was used to 
complement written feedback in association with evaluation questions 1–4 (scientific focus and quality, 
doctoral training, societal impact, cooperation) and in addition to the category evaluating the fitness for 
participation in the evaluation. Panellists used the international level as a point of comparison in the 
evaluation. Scoring was not expected to go along with a preset deviation. 
Each of the draft reports were discussed and dealt with by the panel in meetings in Helsinki (from 11 
September to 13 September or from 18 September to 20 September 2011). In these meetings the panels 
also examined the deviations among the scores and finalised the draft reports together. 
The current RC-specific report deals shortly with the background of the evaluation and the terms of 
participation. The main evaluation feedback is provided in the evaluation report, organised according to 
the evaluation questions. The original material provided by the RCs for the panellists has been attached to 
these documents. 
 
 
 
 
 
 
 
 
 
On behalf of the evaluation steering group and office, I sincerely wish to thank you warmly for your 
participation in this evaluation. The effort you made in submitting the data to TUHAT-RIS is gratefully 
acknowledged by the University. We wish that you find this panel feedback useful in many ways. The 
bibliometric profiles may open a new view on your publication forums and provide a perspective for 
discussion on your choice of forums. We especially hope that this evaluation report will help you in setting 
the future goals of your research. 
 
Johanna Björkroth 
Vice-Rector 
Chair of the Steering Group of the Evaluation 
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Panel members 
CHAIR 
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Karolinska Institute, Sweden 
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Erasmus Medical Centre, the Netherlands 
 
Professor Johanna Ivaska 
Molecular cell biology, cell adhesion, cancer biology 
University of Turku, VTT Technical Research Centre, Finland 
 
Professor Olli Lassila  
Immunology, medical microbiology 
University of Turku, Finland 
 
Professor Hans-Christian Pape 
Neuroscience, neurophysiology 
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MA Liisa Ekebom, Assisting Officer, served in TUHAT-RIS updating the 
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3 
 
 
Acronyms and abbreviations applied in the report 
 
External competitive funding 
AF – Academy of Finland 
TEKES - Finnish Funding Agency for Technology and Innovation  
EU - European Union 
ERC - European Research Council 
International and national foundations 
FP7/6 etc. /Framework Programmes/Funding of European Commission 
 
Evaluation marks 
Outstanding (5) 
Excellent  (4) 
Very Good  (3) 
Good  (2) 
Sufficient  (1) 
 
Abbreviations of Bibliometric Indicators 
P - Number of publications 
TCS – Total number of citations 
MCS - Number of citations per publication, excluding self-citations 
PNC - Percentage of uncited publications 
MNCS - Field-normalized number of citations per publication 
MNJS - Field-normalized average journal impact 
THCP10 - Field-normalized proportion highly cited publications (top 10%) 
INT_COV - Internal coverage, the average amount of references covered by the WoS 
WoS – Thomson Reuters Web of Science Databases 
 
Participation category 
Category 1. The research of the participating community represents the international cutting edge in its 
field. 
Category 2. The research of the participating community is of high quality, but the community in its 
present composition has yet to achieve strong international recognition or a clear break-through. 
Category 3. The research of the participating community is distinct from mainstream research, and the 
special features of the research tradition in the field must be considered in the evaluation. 
Category 4. The research of the participating community represents an innovative opening. 
Category 5. The research of the participating community has a highly significant societal impact. 
 
Research focus areas of the University of Helsinki 
Focus area 1: The basic structure, materials and natural resources of the physical world 
Focus area 2: The basic structure of life 
Focus area 3: The changing environment – clean water 
Focus area 4: The thinking and learning human being 
Focus area 5: Welfare and safety 
Focus area 6: Clinical research 
Focus area 7: Precise reasoning 
Focus area 8: Language and culture 
Focus area 9: Social justice 
Focus area 10: Globalisation and social change 
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1 Introduction to the Evaluation 
1.1 RC-specific evaluation reports 
The participants in the evaluation of research and doctoral training were Researcher Communities 
(hereafter referred to as the RC). The RC refers to the group of researchers who registered together in the 
evaluation of their research and doctoral training. Preconditions in forming RCs were stated in the 
Guidelines for the Participating Researcher Communities. The RCs defined themselves whether their 
compositions should be considered well-established or new. 
It is essential to emphasise that the evaluation combines both meta-evaluation1 and traditional 
research assessment exercise and its focus is both on the research outcomes and procedures associated 
with research and doctoral training. The approach to the evaluation is enhancement-led where self-
evaluation constituted the main information. The answers to the evaluation questions formed together 
with the information of publications and other scientific activities an entity that was to be reviewed as a 
whole. 
The present evaluation recognizes and justifies the diversity of research practices and publication 
traditions. Traditional Research Assessment Exercises do not necessarily value high quality research with 
low volumes or research distinct from mainstream research. It is challenging to expose the diversity of 
research to fair comparison. To understand the essence of different research practices and to do justice to 
their diversity was one of the main challenges of the present evaluation method. Understanding the 
divergent starting points of the RCs demanded sensitivity from the evaluators. 
1.2 Aims and objectives in the evaluation 
The aims of the evaluation are as follows: 
 to improve the level of research and doctoral training at the University of Helsinki and to raise 
their international profile in accordance with the University’s strategic policies. The improvement 
of doctoral training should be compared to the University’s policy.2 
 to enhance the research conducted at the University by taking into account the diversity, 
originality, multidisciplinary nature, success and field-specificity, 
 to recognize the conditions and prerequisites under which excellent, original and high-impact 
research is carried out, 
 to offer the academic community the opportunity to receive topical and versatile international 
peer feedback, 
 to better recognize the University’s research potential. 
 to exploit the University’s TUHAT research information system to enable transparency of 
publishing activities and in the production of reliable, comparable data. 
1.3 Evaluation method 
The evaluation can be considered as an enhancement-led evaluation. Instead of ranking, the main aim is to 
provide useful information for the enhancement of research and doctoral training of the participating RCs. 
The comparison should take into account each field of science and acknowledge their special character. 
                                                                
1 The panellists did not read research reports or abstracts but instead, they evaluated answers to the evaluation 
questions, tables and compilations of publications, other scientific activities, bibliometrics or comparable analyses. 
2
 Policies on doctoral degrees and other postgraduate degrees at the University of Helsinki.  
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The comparison produced information about the present status and factors that have lead to success. Also 
challenges in the operations and outcomes were recognized. 
The evaluation approach has been designed to recognize better the significance and specific nature of 
researcher communities and research areas in the multidisciplinary top-level university. Furthermore, one 
of the aims of the evaluation is to bring to light those evaluation aspects that differ from the prevalent 
ones. Thus the views of various fields of research can be described and research arising from various 
starting points understood better. The doctoral training is integrated into the evaluation as a natural 
component related to research. Operational processes of doctoral training are being examined in the 
evaluation. 
 
Five stages of the evaluation method were: 
1. Registration – Stage 1 
2. Self-evaluation – Stage 2 
3. TUHAT3 compilations on publications and other scientific activities4 
4. External evaluation 
5. Public reporting 
1.4 Implementation of the external evaluation 
Five Evaluation Panels 
Five evaluation panels consisted of independent, renowned and highly respected experts. The main 
domains of the panels are: 
1. biological, agricultural and veterinary sciences 
2. medicine, biomedicine and health sciences 
3. natural sciences 
4. humanities 
5. social sciences 
The University invited 10 renowned scientists to act as chairs or vice-chairs of the five panels based on 
the suggestions of faculties and independent institutes. Besides leading the work of the panel, an 
additional role of the chairs was to discuss with other panel chairs in order to adopt a broadly similar 
approach. The panel chairs and vice-chairs had a pre-meeting on 27 May 2011 in Amsterdam. 
The panel compositions were nominated by the Rector of the University 27 April 2011. The participating 
RCs suggested the panel members. The total number of panel members was 50. The reason for a smaller 
number of panellists as compared to the previous evaluations was the character of the evaluation as a 
meta-evaluation. The panellists did not read research reports or abstracts but instead, they evaluated 
answers to the evaluation questions, tables and compilations of publications, other scientific activities, 
bibliometrics and comparable analyses. 
 
The panel meetings were held in Helsinki: 
 On 11–13 September 2011: (1) biological, agricultural and veterinary sciences, (2) medicine, 
biomedicine and health sciences and (3) natural sciences.  
 On 18–20 September 2011: (4) humanities and (5) social sciences. 
  
                                                                
3 TUHAT (acronym) of Research Information System (RIS) of the University of Helsinki 
4 Supervision of thesis, prizes and awards, editorial work and peer reviews, participation in committees, boards and 
networks and public appearances. 
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1.5 Evaluation material 
The main material in the evaluation was the RCs’ self-evaluations that were qualitative in character and 
allowed the RCs to choose what was important to mention or emphasise and what was left unmentioned. 
The present evaluation is exceptional at least in the Finnish context because it is based on both the 
evaluation documentation (self-evaluation questions, publications and other scientific activities) and the 
bibliometric reports. All documents were delivered to the panellists for examination. 
Traditional bibliometrics can be reasonably done mainly in medicine, biosciences and natural sciences 
when using the Web of Science database, for example. Bibliometrics, provided by CWTS/The Centre for 
Science and Technology Studies, University of Leiden, cover only the publications that include WoS 
identification in the TUHAT-RIS. 
Traditional bibliometrics are seldom relevant in humanities and social sciences because the 
international comparable databases do not store every type of high quality research publications, such as 
books and monographs and scientific journals in other languages than English. The Helsinki University 
Library has done analysis to the RCs, if their publications were not well represented in the Web of Science 
databases (RCs should have at least 50 publications and internal coverage of publications more than 40%) 
– it meant 58 RCs. The bibliometric material for the evaluation panels was available in June 2011. The RC-
specific bibliometric reports are attached at the end of each report. 
The panels were provided with the evaluation material and all other necessary background information, 
such as the basic information about the University of Helsinki and the Finnish higher education system. 
 
Evaluation material 
1. Registration documents of the RCs for the background information 
2. Self evaluation material – answers to the evaluation questions 
3. Publications and other scientific activities based on the TUHAT RIS: 
3.1. statistics of publications 
3.2. list of publications 
3.3. statistics of other scientific activities 
3.4. list of other scientific activities 
4. Bibliometrics and comparable analyses: 
4.1. Analyses of publications based on the verification of TUHAT-RIS publications with the Web 
of Science publications (CWTS/University of Leiden) 
4.2. Publication statistics analysed by the Helsinki University Library - mainly for humanities and 
social sciences 
5. University level survey on doctoral training (August 2011) 
6. University level analysis on publications 2005–2010 (August 2011) provided by CWTS/University 
of Leiden 
 
Background material 
 
University of Helsinki 
- Basic information about the University of the Helsinki 
- The structure of doctoral training at the University of Helsinki 
- Previous evaluations of research at the University of Helsinki – links to the reports: 1998 and 2005 
 
The Finnish Universities/Research Institutes 
- Finnish University system 
- Evaluation of the Finnish National Innovation System 
- The State and Quality of Scientific Research in Finland. Publication of the Academy of Finland 
9/09. 
 
The evaluation panels were provided also with other relevant material on request before the meetings in 
Helsinki. 
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1.6 Evaluation questions and material 
The participating RCs answered the following evaluation questions which are presented according to the 
evaluation form. In addition, TUHAT RIS was used to provide the additional material as explained. For 
giving the feedback to the RCs, the panellists received the evaluation feedback form constructed in line 
with the evaluation questions: 
 
1. Focus and quality of the RC’s research 
 Description of 
- the RC’s research focus. 
- the quality of the RC’s research (incl. key research questions and results) 
- the scientific significance of the RC’s research in the research field(s) 
 Identification of the ways to strengthen the focus and improve the quality of the RC’s research 
The additional material: TUHAT compilation of the RC’s publications, analysis of the RC’s publications data 
(provided by University of Leiden and the Helsinki University Library) 
A written feedback from the aspects of: scientific quality, scientific significance, societal impact, 
innovativeness 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
2. Practises and quality of doctoral training 
 Organising of the doctoral training in the RC. Description of the RC’s principles for: 
- recruitment and selection of doctoral candidates 
- supervision of doctoral candidates 
- collaboration with faculties, departments/institutes, and potential graduate schools/doctoral 
programmes 
- good practises and quality assurance in doctoral training 
- assuring of good career perspectives for the doctoral candidates/fresh doctorates 
 Identification of the RC’s strengths and challenges related to the practises and quality of doctoral 
training, and the actions planned for their development. 
The additional material: TUHAT compilation of the RC’s other scientific activities/supervision of doctoral 
dissertations 
A written feedback from the aspects of: processes and good practices related to leadership and 
management 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
3. The societal impact of research and doctoral training 
 Description on how the RC interacts with and contributes to the society (collaboration with 
public, private and/or 3rd sector). 
 Identification of the ways to strengthen the societal impact of the RC’s research and doctoral 
training. 
The additional material: TUHAT compilation of the RC’s other scientific activities. 
A written feedback from the aspects of: societal impact, national and international collaboration, 
innovativeness 
 
  Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
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4. International and national (incl. intersectoral) research collaboration and researcher mobility 
 Description of  
- the RC’s research collaborations and joint doctoral training activities 
- how the RC has promoted researcher mobility 
 Identification of the RC’s strengths and challenges related to research collaboration and 
researcher mobility, and the actions planned for their development. 
A written feedback from the aspects of: scientific quality, national and international collaboration 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
5. Operational conditions  
 Description of the operational conditions in the RC’s research environment (e.g. research 
infrastructure, balance between research and teaching duties). 
 Identification of the RC’s strengths and challenges related to operational conditions, and the 
actions planned for their development. 
A written feedback from the aspects of: processes and good practices related to leadership and 
management 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
6. Leadership and management in the researcher community 
 Description of 
- the execution and processes of leadership in the RC 
- how the management-related responsibilities and roles are distributed in the RC 
- how the leadership- and management-related processes support 
- high quality research 
- collaboration between principal investigators and other researchers in the RC 
the RC’s research focus 
- strengthening of the RC’s know-how 
 Identification of the RC’s strengths and challenges related to leadership and management, and 
the actions planned for developing the processes 
 
7. External competitive funding of the RC 
 The RCs were asked to provide information of such external competitive funding, where: 
- the funding decisions have been made during 1.1.2005-31.12.2010, and 
- the administrator of the funding is/has been the University of Helsinki 
 On the e-form the RCs were asked to provide: 
1) The relevant funding source(s) from a given list (Academy of Finland/Research Council, TEKES/The 
Finnish Funding Agency for Technology and Innovation , EU, ERC, foundations, other national funding 
organisations, other international funding organisations), and 
2)The total sum of funding which the organisation in question had decided to allocate to the RCs 
members during 1.1.2005–31.12.2010. 
 
Competitive funding reported in the text is also to be considered when evaluating this point. 
A written feedback from the aspects of: scientific quality, scientific significance, societal impact, 
innovativeness, future significance 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
8. The RC’s strategic action plan for 2011–2013 
 RC’s description of their future perspectives in relation to research and doctoral training. 
A written feedback from the aspects of: scientific quality, scientific significance, societal Impact, processes 
and good practices related to leadership and management, national and international collaboration, 
innovativeness, future significance 
 Strengths 
 Areas of development 
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 Other remarks 
 Recommendations 
 
9. Evaluation of the category of the RC in the context of entity of the evaluation material (1-8) 
 
The RC’s fitness to the chosen participation category 
A written feedback evaluating the RC’s fitness to the chosen participation category  
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
10. Short description of how the RC members contributed the compilation of the stage 2 material 
Comments on the compilation of evaluation material 
 
11. How the UH’s focus areas are presented in the RC’s research? 
Comments if applicable 
 
12. RC-specific main recommendations based on the previous questions 1–11 
 
13. RC-specific conclusions 
1.7 Evaluation criteria 
The panellists were expected to give evaluative and analytical feedback to each evaluation question 
according to their aspects in order to describe and justify the quality of the submitted material. In 
addition, the evaluation feedback was asked to be pointed out the level of the performance according to 
the following classifications: 
 outstanding  (5) 
 excellent  (4) 
 very good  (3) 
 good   (2) 
 sufficient  (1) 
 
Evaluation according to the criteria was to be made with thorough consideration of the entire 
evaluation material of the RC in question. Finally, in questions 1-4 and 9, the panellists were expected to 
classify their written feedback into one of the provided levels (the levels included respective descriptions, 
‘criteria’). Some panels used decimals in marks. The descriptive level was interpreted according to the 
integers and not rounding up the decimals by the editors. 
 
Description of criteria levels 
Question 1 – FOCUS AND QUALITY OF THE RC’S RESEARCH 
 
Classification: Criteria (level of procedures and results) 
Outstanding quality of procedures and results (5) 
Outstandingly strong research, also from international perspective. Attracts great international 
interest with a wide impact, including publications in leading journals and/or monographs published 
by leading international publishing houses. The research has world leading qualities. The research 
focus, key research questions scientific significance, societal impact and innovativeness are of 
outstanding quality. 
In cases where the research is of a national character and, in the judgement of the evaluators, should 
remain so, the concepts of ”international attention” or ”international impact” etc. in the grading 
criteria above may be replaced by ”international comparability”. 
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Operations and procedures are of outstanding quality, transparent and shared in the community. The 
improvement of research and other efforts are documented and operations and practices are in 
alignment with the documentation. The ambition to develop the community together is of 
outstanding quality. 
Excellent quality of procedures and results (4) 
Research of excellent quality. Typically published with great impact, also internationally. Without 
doubt, the research has a leading position in its field in Finland. 
Operations and procedures are of excellent quality, transparent and shared in the community. The 
improvement of research and other efforts are documented and operations and practices are to 
large extent in alignment with the documentation. The ambition to develop the community together 
is of excellent quality. 
Very good quality of procedures and results (3) 
The research is of such very good quality that it attracts wide national and international attention. 
Operations and procedures are of very good quality, transparent and shared in the community. The 
improvement of research and other efforts are documented and operations and practices are to 
large extent in alignment with the documentation. The ambition to develop the community together 
is of very good quality. 
Good quality of procedures and results (2) 
Good research attracting mainly national attention but possessing international potential, 
extraordinarily high relevance may motivate good research. 
Operations and procedures are of good quality, shared occasionally in the community. The 
improvement of research and other efforts are occasionally documented and operations and 
practices are to large extent in alignment with the documentation. The ambition to develop the 
community together is of good quality. 
Sufficient quality of procedures and results (1) 
In some cases the research is insufficient and reports do not gain wide circulation or do not have 
national or international attention. Research activities should be revised. 
Operations and procedures are of sufficient quality, shared occasionally in the community. The 
improvement of research and other efforts are occasionally documented and operations and 
practices are to some extent in alignment with the documentation. The ambition to develop the 
community together is of sufficient quality. 
 
Question 2 – DOCTORAL TRAINING 
Question 3 – SOCIETAL IMPACT 
Question 4 – COLLABORATION 
 
Classification: Criteria (level of procedures and results) 
Outstanding quality of procedures and results (5) 
Procedures are of outstanding quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
management are documented and operations and practices are in alignment with the 
documentation. The ambition to develop the community together is of outstanding quality. The 
procedures and results are regularly evaluated and the feedback has an effect on the planning. 
Excellent quality of procedures and results (4) 
Procedures are of excellent quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
management are documented and operations and practices are to large extent in alignment with the 
documentation. The ambition to develop the community together is of excellent quality. The 
procedures and outcomes are evaluated and the feedback has an effect on the planning. 
Very good quality of procedures and results (3) 
Procedures are of very good quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
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management are documented and operations and practices are to large extent in alignment with the 
documentation. The ambition to develop the community together is of very good quality. 
Good quality of procedures and results (2) 
Procedures are of good quality, shared occasionally in the community. The practices and quality of 
doctoral training/societal impact/international and national collaboration/leadership and 
management are documented and operations and practices are to large extent in alignment with the 
documentation. The ambition to develop the community together is of good quality. 
Sufficient quality of procedures and results (1) 
Procedures are of sufficient quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
management are occasionally documented and operations and practices are to some extent in 
alignment with the documentation. The ambition to develop the community together is of sufficient 
quality. 
 
Question 9 – CATEGORY 
Participation category – fitness for the category chosen 
The choice and justification for the chosen category below should be reflected in the RC’s responses to the 
evaluation questions 1–8. 
1. The research of the participating community represents the international cutting edge in its field. 
2. The research of the participating community is of high quality, but the community in its present 
composition has yet to achieve strong international recognition or a clear break-through. 
3. The research of the participating community is distinct from mainstream research, and the special 
features of the research tradition in the field must be considered in the evaluation. The research is 
of high quality and has great significance and impact in its field. However, the generally used 
research evaluation methods do not necessarily shed sufficient light on the merits of the 
research.  
4. The research of the participating community represents an innovative opening. A new opening can 
be an innovative combination of research fields, or it can be proven to have a special social, 
national or international demand or other significance. Even if the researcher community in its 
present composition has yet to obtain proof of international success, its members can produce 
convincing evidence of the high level of their previous research. 
5. The research of the participating community has a highly significant societal impact. The 
participating researcher community is able to justify the high social significance of its research. 
The research may relate to national legislation, media visibility or participation in social debate, 
or other activities promoting social development and human welfare. In addition to having 
societal impact, the research must be of a high standard. 
 
An example of outstanding fitness for category choice (5) 5 
The RC’s representation and argumentation for the chosen category were convincing. The RC recognized 
its real capacity and apparent outcomes in a wider context to the research communities. The specific 
character of the RC was well-recognized and well stated in the responses. The RC fitted optimally for the 
category. 
 
 Outstanding  (5) 
 Excellent  (4) 
 Very good  (3) 
 Good   (2) 
 Sufficient  (1) 
The above-mentioned definition of outstanding was only an example in order to assist the panellists in 
the positioning of the classification. There was no exact definition for the category fitness. 
                                                                
5 The panels discussed the category fitness and made the final conclusions of the interpretation of it. 
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1.8 Timetable of the evaluation 
The main timetable of the evaluation: 
1. Registration   November 2010 
2. Submission of self-evaluation materials  January–February 2011 
3. External peer review    May–September 2011 
4. Published reports    March–April 2012 
- University level public report 
- RC specific reports 
 
The entire evaluation was implemented during the university’s strategy period 2010–2012. The preliminary 
results were available for the planning of the following strategy period in late autumn 2011. The evaluation 
reports will be published in March/April 2012. More detailed time schedule is published in the University 
report. 
1.9 Evaluation feedback – consensus of the entire panel 
The panellists evaluated all the RC-specific material before the meetings in Helsinki and mailed the 
draft reports to the evaluation office. The latest interim versions were on-line available to all the panellists 
on the Wiki-sites. In September 2011, in Helsinki the panels discussed the material, revised the first draft 
reports and decided the final numeric evaluation. After the meetings in Helsinki, the panels continued 
working and finalised the reports before the end of November 2011. The final RC-specific reports are the 
consensus of the entire panel. 
The evaluation reports were written by the panels independently. During the editing process, the 
evaluation office requested some clarifications from the panels when necessary. The tone and style in the 
reports were not harmonized in the editing process. All the reports follow the original texts written by the 
panels as far as it was possible. 
The original evaluation material of the RCs, provided for the panellists is attached at the end of the 
report. It is essential to notice that the exported lists of publications and other scientific activities depend 
how the data was stored in the TUHAT-RIS by the RCs. 
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2 Evaluation feedback 
2.1 Focus and quality of the RC’s research 
 Description of 
 the RC’s research focus 
 the quality of the RC’s research (incl. key research questions and results) 
 the scientific significance of the RC’s research in the research field(s) 
 Identification of the ways to strengthen the focus and improve the quality of the RC’s research 
ASPECTS: Scientific quality, scientific significance, societal impact, innovativeness 
 
PDBD consists of a total of 32 researches at the Division of Pharmacology and Toxicology, with roughly 
40/60 financed by Helsinki University and external funds, respectively. The RC is characterized by a 
focused research profile on the pharmacology of neurodegenerative diseases particularly Parkinson’s 
disease (PD). The RC has a clear focus, groups are linked by numerous mutual connections in research and 
teaching. 
The topic is an important one, in both basic and clinical terms, it is distinctively different from that of 
other units at Helsinki University, and the PIs have made significant contributions to the field. The overall 
publication output of PDBD is very good, given the size of the RC and the research field of 
pharmacological neuroscience. There is an average of around 25 publications/year, with a vast majority 
(>70%) in competitive and good journals of pharmacology/neuroscience, and a number (10-15%) in high-
rank journals. One highlight is the identification of CDNF (cerebral dopamine neurotrophic factor), a novel 
neurotrophic factor with protective potential in experimental models of PD, published in Nature 2007. 
Overall, the scientific quality and significance are very good. The RC’s plans on extending their approaches 
towards more mechanistic studies on the one and systems-oriented studies on the other hand, indicate a 
valid and realistic strategy. 
Overall, this RC marks a high standard at national rank, a convincingly focused and distinctive research 
strategy with an excellent potential for identification of clinically relevant mechanisms/ substances, and 
thereby provides a promising basis for extension towards high international rank. 
Numeric evaluation: 4 (Excellent) 
2.2 Practises and quality of doctoral training 
 Organising of the doctoral training in the RC. Description of the RC’s principles for: 
 recruitment and selection of doctoral candidates 
 supervision of doctoral candidates 
 collaboration with faculties, departments/institutes, and potential graduate schools/doctoral 
programmes 
 good practises and quality assurance in doctoral training 
 assuring of good career perspectives for the doctoral candidates/fresh doctorates 
 Identification of the RC’s strengths and challenges related to the practises and quality of doctoral 
training, and the actions planned for their development. 
 Additional material: TUHAT compilation of the RC’s other scientific activities/supervision of doctoral 
dissertations 
ASPECTS: Processes and good practices related to leadership and management 
 
Doctoral training has been excellently organized at the Graduate School in Pharmaceutical Research 
(GPSR), funded by the Academy of Finland and Ministry of Education and Culture. This applies to 
recruitment (open international call) and selection (high quality criteria; GSPR board), systematic 
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organization of the training (structured, step-wise program), thesis committee, mobility (travel grants), 
and internationality of the doctoral students. The numbers are impressive (total of 150 students, steady 
increase in graduations), the quality is very high, and the RC should be congratulated for its maintained 
effort. Adding to this very positive overall scenario is the close career follow-up of the graduates, 
demonstrating a 100% employment rate in academia and/or industry. 
One future challenge, as indicated, will be to merge the major Grad Schools in Pharmacology in 
Finland, and the RC should be encouraged to take the lead. Overall, the GPSR makes a most valuable 
contribution to the portfolio of Helsinki University, which might consider an increase in support of the RC 
(taking into consideration the heavy teaching load of the PIs). 
Numeric evaluation: 5 (Outstanding) 
2.3 The societal impact of research and doctoral training 
 Description on how the RC interacts with and contributes to the society (collaboration with public, 
private and/or 3rd sector). 
 Identification of the ways to strengthen the societal impact of the RC’s research and doctoral training. 
 Additional material: TUHAT compilation of the RC’s other scientific activities. 
ASPECTS: Societal impact, national and international collaboration, innovativeness 
 
The most significant societal impact of PDBD results from the research relating to one of the most 
frequent neurodegenerative diseases, the identification of pathogenetic and pathophysiological 
mechanisms, and the potential of generating novel pharmacological items of potential therapeutic 
relevance. The research of PDBD is key to drug development and application, and therefore is of very high 
societal impact. 
The RC has excellently exploited the possibilities to present these issues to the public, public 
authorities relating to drug development and legislation issues in the health sector. The RC should be 
encouraged to further use and better develop translational strategies, for instance by seeking interaction 
with pharmaceutical industries. The PIs certainly have the expertise, and a more offensive translational 
approach might further strengthen the role of PDBD at Helsinki University. The possibilities for therapy 
development or drug development should be worked out, may be by an interdisciplinary approach with 
other RCs. As universities have difficulties in taking care of the whole value chain in such development 
lines, some concepts and proof of concepts could give successful lines. 
Numeric evaluation: 4 (Excellent) 
2.4 International and national (incl. intersectoral) research 
collaboration and researcher mobility 
 Description of  
 the RC’s research collaborations and joint doctoral training activities 
 how the RC has promoted researcher mobility 
 Identification of the RC’s strengths and challenges related to research collaboration and researcher 
mobility, and the actions planned for their development. 
ASPECTS: Scientific quality, national and international collaboration 
 
The PDBD PIs are actively involved in two European collaborations (EraNet Neuron on CDNF and NeuroPro 
on POP), one US collaboration (MJFF), were part of the EU ProKinaseResearch consortium, and are 
particularly productive as part of EU NeuroPro. The GPSR Grad School is approached by international 
candidates on a regular basis. Overall, this is a very appreciable effort, complemented by numerous 
collaborations on a national basis. Actions planned for the future focus on ERC, NIH applications, which 
appears to be a feasible strategy. 
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With such a high standing of this RC it may be useful to approach other groups in the same or in other 
universities or local pharmaceutical industry for an increased interaction. 
Numeric evaluation: 4 (Excellent) 
2.5 Operational conditions 
 Description of the operational conditions in the RC’s research environment (e.g. research 
infrastructure, balance between research and teaching duties). 
 Identification of the RC’s strengths and challenges related to operational conditions, and the actions 
planned for their development. 
ASPECTS: Processes and good practices related to leadership and management 
 
Research environment and technical infrastructure, including the excellent core facilities at Viikki and 
Meilahti campus, seem to be adequate, with one significant exception: lack of appropriate animal facilities. 
Helsinki University should undertake all necessary steps for improvement of the situation, finalize the 
central animal facility and provide adequate animal facilities/experimental labs for in vivo studies, in order 
to assure research of PDBD. 
Teaching load seems particularly heavy (28% of the ECTS points, 27% masters, 13% PhD thesis of the 
Faculty of Pharmacy). Apparent is skilful organization of the teaching, and the willingness and “pride” to 
teach. The PIs should be congratulated on this spirit. 
There seems a specific need of renewing a professor’s position after retirement, and funding of post-
docs on a longer time scale (5 year period). It is recommended that Helsinki University evaluates the 
situations, if applicable, improves the conditions and generally prepares in advance where issues of 
sustainability arise for senior staff replacement so that research activities are minimally disrupted. 
2.6 Leadership and management in the researcher community 
 Description of  
 the execution and processes of leadership in the RC 
 how the management-related responsibilities and roles are distributed in the RC 
 how the leadership- and management-related processes support 
 high quality research 
 collaboration between principal investigators and other researchers in the RC 
 the RC’s research focus 
 strengthening of the RC’s know-how 
 Identification of the RC’s strengths and challenges related to leadership and management, and the 
actions planned for developing the processes 
ASPECTS: Processes and good practices related to leadership and management 
 
The organizational structure goes along a traditional route (full professors in charge), and there seems to 
be no need for a change (see pt. 2.1, 2.2, 2.5). 
2.7 External competitive funding of the RC 
• The RCs were asked to provide information of such external competitive funding, where: 
• the funding decisions have been made during 1.1.2005–31.12.2010, and  
• the administrator of the funding is/has been the University of Helsinki 
• On the e-form the RCs were asked to provide: 
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1) The relevant funding source(s) from a given list (Academy of Finland/Research Council, 
TEKES/The Finnish Funding Agency for Technology and Innovation, EU, ERC, foundations, other 
national funding organisations, other international funding organizations), and 
2) The total sum of funding which the organisation in question had decided to allocate to the RCs 
members during 1.1.2005–31.12.2010. 
Competitive funding reported in the text is also to be considered when evaluating this point. 
ASPECTS: Scientific quality, scientific significance, societal impact, innovativeness and future significance 
 
Extra-mural funding amounts to a total of appr 3.5 Mill €. In view of the overall size of the RC, this marks 
an appreciable starting point. 
2.8 The RC’s strategic action plan for 2011–2013 
• RC’s description of their future perspectives in relation to research and doctoral training. 
ASPECTS: Scientific quality, scientific significance, societal Impact, processes and good practices related to 
leadership and management, national and international collaboration, innovativeness, future significance 
 
The RC’s action plan builds on the status quo, identifies current shortages (personnel, infrastructure, see 
pt. 2.5) and strengths (doctoral program, see pt. 2.2), and convincingly presents plans on more 
mechanistic and systemic approaches (see pt. 2.1), and on increasing extra-mural funding through 
translational efforts. This is overall convincing and apt to improve the distinctive role of PDBD at Helsinki 
University. 
2.9 Evaluation of the category of the RC in the context of entity of 
the evaluation material (1-8) 
The RC’s fitness to the chosen participation category. 
Category 2. The research of the participating community is of high quality, but the community in its present 
composition has yet to achieve strong international recognition or a clear break-through. 
 
The focused neuroscientific topic and the pharmacological expertise of PDBD bear a large potential of 
innovation and translation with great scientific and social impact. This is certainly evident at the national 
level, and the RC is on its way towards international excellence (for details see remarks above: pts 2.1, 2.2, 
2.6, 2.8). 
Numeric evaluation: 4 (Excellent) 
2.10 Short description of how the RC members contributed the 
compilation of the stage 2 material 
The processes employed were fair and appropriate. 
2.11 How the UH’s focus areas are presented in the RC’s research 
Focus area 2: The basic structure of life 
 
Overall, research of the PIs of PDBD is clearly part of UH’s focus on “Basic Structure of Life”. 
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2.12 RC-specific main recommendations 
The proposal for the RC to extend their research activities to approach both mechanistic and system 
orientated studies is seen as an appropriate and sound strategy, and supported by the Panel. 
Attention should be given to a concerted effort to achieve publication of research outputs in high 
impact journals which will assist in enhancing the international standing and reputation of the RC. 
It is recommended that the RC takes an active and leading role in the planned merger of the graduate 
schools in pharmacology. 
Given the possibilities arising from drug development, consideration should be given to extending the 
‘value chain’ by enhancing multidisciplinarity via collaborations with other RCs in the field. Such 
collaborations could add strength to future grant applications. 
The Panel also wish to recommend that the issues arising from the retirement of a senior professorial PI 
are evaluated by UH, and succession planning addressed. 
2.13 RC-specific conclusions 
The Panel were pleased to note the clear and distinct areas of research of the RC and the focused nature of 
the work, as well as the contribution to knowledge in the field of Parkinson’s disease. Especially impressive 
were the efforts and contributions made by the RC to the GSPR and the doctoral training programmes. 
Plans to collaborate meaningfully with other RCs in the field should be considered in an attempt to 
extend the ‘value chain’ of the research within the UH. 
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3 Appendices 
A. Original evaluation material 
a. Registration material – Stage 1 
b. Answers to evaluation questions – Stage 2 
c. List of publications 
d. List of other scientific activities 
B. Bibliometric analyses 
a. Analysis provided by CWTS/University of Leiden 
b. Analysis provided by Helsinki University Library (66 RCs) 
 
 
 
 
 
International evaluation of research and doctoral training 
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         RC-SPECIFIC MATERIAL FOR THE PEER REVIEW 
 
 
 
 
NAME OF THE RESEARCHER COMMUNITY:  
Pharmacology of Degenerative Brain Diseases (PDBD) 
 
LEADER OF THE RESEARCHER COMMUNITY:  
Professor Raimo Tuominen, Faculty of Pharmacy 
 
 
RC-SPECIFIC MATERIAL FOR THE PEER REVIEW: 
 Material submitted by the RC at stages 1 and 2 of the evaluation 
- STAGE 1 material: RC’s registration form (incl. list of RC participants in an excel table) 
- STAGE 2 material: RC’s answers to evaluation questions 
 TUHAT compilations of the RC members’ publications 1.1.2005-31.12.2010 
 TUHAT compilations of the RC members’ other scientific activities 1.1.2005-31.12.2010 
 Web of Science(WoS)-based bibliometrics of the RC’s publications data 1.1.2005-31.12.2010 
(analysis carried out by CWTS, Leiden University) 
NB! Since Web of Science(WoS)-based bibliometrics does not provide representative results for most RCs representing 
humanities, social sciences and computer sciences, the publications of these RCs will be analyzed by the UH Library 
(results available by the end of June, 2011) 
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INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC STAGE 1 MATERIAL (registration form) 
 
 
 
 
Name: Tuominen, Raimo 
E-mail:  
Phone: +358-9-191-59469 
Affiliation: Professor 
Street address: Viikinkaari 5E, 00790 Helsinki 
 
 
Name of the participating RC (max. 30 characters): Pharmacology of Degenerative Brain Diseases 
Acronym for the participating RC (max. 10 characters): PDBD 
Description of the operational basis in 2005-2010 (eg. research collaboration, joint doctoral training 
activities) on which the RC was formed (MAX. 2200 characters with spaces): In practical means, the 
Research Community “Pharmacology of Degenerative Brain Diseases (PDBD)”, is mostly based on the work 
done at the Division of Pharmacology and Toxicology, Faculty of Pharmacy, but a significant part also with 
collaboration with other research units in Finland and abroad, including sites of the PI’s former professor 
affiliations. In Viikki Campus, the main collaborators have been the Neuroscience Center and Institute of 
Biotechnology whose excellent instruments have also been widely used. The RC evaluation is based on the 
work of 32 researchers of which 9 affiliations (2 professors, 3 university lecturers, 1 instructor and 3 
doctoral candidates) are paid by the University of Helsinki. The rest of the staff (4 senior scientists and 16 
doctoral candidates) are paid by external funding. In addition, the evaluation includes research done by 8 
post-doctoral researchers who were graduated from the RC. The research done by the RC is basic 
pharmacology of major degenerative brain diseases, especially that of Parkinson’s disease, but also 
Alzheimer’s  disease and addiction. In our opinion the RC has a research profile that distinct from other 
units of the Viikki Campus and the University of Helsinki. Within the frame work of Graduate School of 
Pharmaceutical Sciences the RC has a productive collaboration with the Pharmacology Unit of the 
University of Eastern Finland (formerly University of Kuopio). The results by the RC have been published in 
high impact international scientific peer reviewed journals, mostly in the fields of neuroscience and 
neuropharmacology. Doctoral training has been active, including continuous international collaboration. 
Several doctoral students have done short visits to laboratories abroad in order to learn new methods and 
to do collaborative research. These include several visits to USA, Russia and UK. In addition, we have hosted 
tens of international visitors in our unit. 
 
 
Main scientific field of the RC’s research: medicine, biomedicine and healt sciences 
RC's scientific subfield 1: Pharmacology and Pharmacy 
RC's scientific subfield 2: Neurosciences 
1 RESPONSIBLE PERSON 
2 DESCRIPTION OF THE PARTICIPATING RESEARCHER COMMUNITY (RC) 
3 SCIENTIFIC FIELDS OF THE RC 
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UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC STAGE 1 MATERIAL (registration form) 
 
 
RC's scientific subfield 3: Medicine, Research and Experimental 
RC's scientific subfield 4: Substance Abuse 
Other, if not in the list: Neuropharmacology 
Neurodegeneration 
Behavioral nuroscience 
Parkinson's disease 
Discovery of new drugs and drug targets 
 
 
Participation category: 2. Research of the participating community is of high quality, but the community in 
its present composition has yet to achieve strong international recognition or a clear break-through 
Justification for the selected participation category (MAX. 2200 characters with spaces):  The RC 
represents internationally acknowledged high level research, but in our own estimate we can still improve 
our actions. The results by the RC have been published in high impact international scientific peer reviewed 
journals, mostly in the fields of neuroscience and neuropharmacology. The PIs of the RC have been have 
been members of editorial boards and reviewers of international grant applications. They have been invited 
to review numerous manuscripts in peer reviewed journals. The researchers of the RC have given oral and 
poster presentations in international congresses. Although the PI’s have been invited to give lectures in 
international congresses, invitations to give plenary lectures have been scarce.  Doctoral training has been 
active, including continuous international collaboration. Several doctoral students have done short visits to 
laboratories abroad in order to learn new methods and to do collaborative research. These include several 
visits to USA, Russia and UK. In addition, we have hosted tens of international visitors in our unit. The 
ongoing research show exciting results, but those cannot be included in this evaluation. The RC represents 
internationally acknowledged high level research, but in our own estimate the cutting edge in the area 
remains to be achieved. With this background information we decided to go for the category 2 in the 
evaluation. 
 
 
Public description of the RC's research and doctoral training (MAX. 2200 characters with spaces): The 
research community Pharmacology of degenerative brain diseases focuses on diseases related to brain 
dopamine. In Parkinson’s disease specific dopamine neurons die while in addiction distinct dopamine 
neurons are overactive. In the body, dopamine and its precursor levodopa are metabolized by catechol-O-
methyltransferase (COMT). We have obtained new evidence supporting beneficial effects of COMT-
inhibitors as L-dopa adjuncts in the treatment of Parkinson’s disease. This treatment increases brain 
dopamine. An original finding is their analgesic effect in animal models of neuropathic pain which may open 
new therapeutic possibilities. COMT is the key modulator of dopaminergic activity in those brain areas that 
regulate pleasure and motivation. In COMT defective mice, addictive effects of alcohol and nicotine were 
enhanced. Neurotrophic factors are essential for well being of dopamine neurons in the brain and may be 
useful in Parkinson’s disease. A new factor, CDNF (cerebral dopamine neurotrophic factor) has been 
discovered in the University of Helsinki. In experimental Parkinson model degeneration of dopamine 
neurons was prevented by CDNF and other trophic factors, GDNF, MANF and VEGF. Gene modified mice 
4 RC'S PARTICIPATION CATEGORY 
5 DESCRIPTION OF THE RC'S RESEARCH AND DOCTORAL TRAINING 
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RC-SPECIFIC STAGE 1 MATERIAL (registration form) 
 
 
with constantly overactive receptor for GDNF have very high concentrations of dopamine in the brain. Our 
results indicate that prolyl oligopeptidase (POP) may have a role in Parkinson’s diseases and multiple 
sclerosis. POP is widely distributed in the body and it is involved in the processing of -synuclein protein 
that is involved in pathology of Parkinson’s disease. Effects of specific POP-inhibitors on these harmful 
processes are being studied. Nicotine, one of the most addictive substances, sensitizes brain dopamine 
system, and it is also active in an animal model of Parkinson’s disease due to dopamine release in striatum. 
Chronic nicotine increased the number of its own intracellular receptors which may serve as reservoir pool. 
These projects have lured tens of doctoral students whose studies were organized according the rules of a 
well functioning Graduate School of Pharmaceutical Research. 
Significance of the RC's research and doctoral training for the University of Helsinki (MAX. 2200 
characters with spaces): Research done at the RC’s laboratories helps to realize the strategy of the 
University of Helsinki to be the ”most comprehensive research institution in Finland” and “confirm its 
position among the world’s best multi disciplinary research universities”. Our research is internationally 
acknowledged and it adds to the basic knowledge of degenerative brain diseases and their future drug 
treatments. In the University of Helsinki, neuroscience among other biomedical sciences has been very 
successful and highly ranked in international evaluations.  Our fund raising from external sources has been 
successful. We have received research support from European Union framework programs for studies on 
POP and protein kinase targeted drugs as well as studies on neurotrophic factors in Parkinson’s disease.  
The latter has been funded also by the Micahel J Fox Foundation for Parkinson’s disease. Majority of 
funding has been from domestic sources including the Academy of Finland, Sigrid Juselius Foundation and 
the Jane and Aatos Erkko Foundation. Several of our doctoral students have been supported by the Finnish 
Parkinson Foundation. Our research has gained publicity in the form of TV- interviews, magazine - and news 
paper articles. We have close interaction with the Finnish patient organization for Parkinson’s disease and 
we write often articles to their journal. The RC has been active in doctoral training in the Graduate School 
of Pharmaceutical Research and in the frame work of FinPharmaNet, a network of Finnish graduate schools 
in the field of drug research, see http://finpharmanet.utu.fi/ 
Our doctoral graduates have been working as post-doctoral students in Switzerland,  the Netherlands, and 
in the US.  Some of the graduates are employed by the University of Helsinki, the Finnish Medicines Agency 
and pharmaceutical industry. 
Keywords: Catechol-O-methyltransferase, COMT;  
Prolyl oligopeptidase, POP;  
Dopamine;  
Parkinson’s disease;  
Protein kinase C, PKC;  
Rat;  
Brain;  
Degenerative brain disease;  
Nicotine;  
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Nicotinic acetylcholine receptor, nAChR;  
Cerebral dopamine neurotrophic factor, CDNF;  
Glial cell line derived neurotrophic factor, GDNF; Microdialysis;  
Addiction 
 
 
Justified estimate of the quality of the RC's research and doctoral training at national and international 
level during 2005-2010 (MAX. 2200 characters with spaces): The results by the Pharmacology of 
Degenerative Brain Diseases (PDBD)  RC have been published in journals with high impact factors mostly in 
the fields of neuroscience and neuropharmacology. The forums include Nature (IF 34.48), Journal of 
Neuroscience (7.178),  Neurobiology of Aging (5.937), British Journal of Pharmacology (5.204), Journal of 
Medicinal Chemistry (4.802), Developmental biology (4.379), Journal of Neurochemistry (3.999), European 
Journal of Neuroscience (3.418), European Journal of Pharmacology (2.585) and European Journal of 
Pharmaceutical Sciences (2.608).  Our research has also been strongly oriented to drug discovery, including 
pharmacology of novel compounds targeted to POP, COMT and protein kinase C (PKC). This is reflected by 
number of publications in the top ranking journal for new chemical entities. The RC has been involved in 
three European Union funded research projects, and in one of them (Pro-KinaseResearch, largest health 
project within the FP6) as the coordinator. In addition to this, there are other international and national 
collaborative research projects with laboratories in the US, Russia, Estonia and UK. The research has been 
funded by international (EU, MJFF) and national (e.g. the Academy of Finland, Sigrid Juselius Foundation, 
Finnish Parkinson Foundation) sources.  
Doctoral training has been significant part of the RC’s activities. The PIs of the RC have been involved in 
total of 13 dissertations as supervisors or co-supervisors of which 8 have been done in the unit. One of the 
latter was awarded as the best thesis in pharmacology in Finland in the year 2009.  One PI has supervised 6 
dissertations that were finished and approved with distinction in his previous affiliation during the follow-
up period. Two PIs of the RC have been appointed as the directors of the Graduate School of 
Pharmaceutical Research for total of 5 years during this period. The graduate school has been productive 
and has received top evaluations from the Academy of Finland. 
Comments on how the RC's scientific productivity and doctoral training should be evaluated (MAX. 2200 
characters with spaces): The evaluation should estimate how the RC meets with the strategic aims of the 
University and the Faculty. Also, how does the research reflect the main focus of research done in the 
Faculty which is has been described as “Preclinical drug research and research on drug discovery and 
development tools”. The outcome should be compared to that of similar size units (9 researchers paid by 
the University and 12 paid by external research funds) and similar load of teaching. This would be 
appropriate and fair.  The relevance of the research hypotheses and results in relation to societal impact 
and unmet needs in prevailing drug therapies should be taken into account. Research methods and 
research infrastructure should be evaluated.  
The impacts of our scientific publications should be in general compared to the impact of the best journals 
in the field of pharmacology.  In addition, we have published many papers in other journals especially in the 
field of neuroscience. As evaluation methods, we suggest the following: 1) number of full publications, 2) 
6 QUALITY OF RC'S RESEARCH AND DOCTORAL TRAINING 
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sum of IFs of the journals, 3) number of Ph.D. degrees per PI and number of years as responsible graduate 
school positions per PI. Since citation numbers accumulate slowly, we think that these are not valid for such 
a short period. If they are used, we recommend full-life citation numbers and H-indexes. External research 
funding during 1.1.2005 – 31.12.2010 should be evaluated. 
Doctoral training can be evaluated based on published PhD theses within the RC own Unit and with 
collaborating Units in the University of Helsinki and in the University of Eastern Finland (formerly University 
of Kuopio). Another basis for evaluation would be the number of Graduate School courses organized by the 
graduate school. Finally, we want to emphasize that all doctors graduated from the program have been 
employed. The Graduate School of Pharmaceutical Research is based on the research groups of the Faculty 
of Pharmacy, University Of Helsinki, and Department of Pharmacy, Faculty of Health Sciences, University of 
Eastern Finland. Director of this graduate school has been from our RC for five years during the period of 
evaluation. 
LIST OF RC MEMBERS
NAME OF THE RESEARCHER COMMUNITY: Pharmacology of Degenerative Brain Diseases
RC-LEADER R. Tuominen
CATEGORY 2
Last name First name
PI-status 
(TUHAT-
check, 
lista 16.11.)
Title of research and 
teaching personnel Affiliation 
1 Männistö Pekka x Professor Faculty of Pharmacy
2 Tuominen Raimo x Professor Faculty of Pharmacy
3 Piepponen Petteri x University Lecturer Faculty of Pharmacy
4 Raasmaja Atso x University Lecturer Faculty of Pharmacy
5 Salminen Outi University Lecturer Faculty of Pharmacy
6 Kivinummi (née Vihavainen) Tanja University Instrucor Faculty of Pharmacy
7 Ekokoski Elina Senior Researcher Faculty of Pharmacy
8 Garcia-Horsman Arturo x Senior Researcher Faculty of Pharmacy
9 Myöhänen Timo Senior Researcher Faculty of Pharmacy
10 Reenilä Ilkka Graduate School Coordintor Faculty of Pharmacy
11 Airavaara Mikko Post-doctoral Researcher NIDA, NIH, USA
12 Janhunen Sanna Senior Researcher Orion Pharma, Finland
13 Kaste (née Marttila) Kristiina Senior member Pharmaceutical Pricing Board
14 Mijatovic Jelena Post-doctoral Researcher Roche,  Switzerland
15 Pakkanen Jukka Senior Researcher Finnish Medicines Agency
16 Tammimäki Anne Post-doctoral Researcher Univ Boulder, CO, USA
17 Tenorio-Larga Jofre Post-doctoral Researcher Faculty of Pharmacy
18 Ahmberg Carolina Doctoral candidate Faculty of Pharmacy
19 Bäck Susanne Doctoral candidate Faculty of Pharmacy
20 Kambur Oleg Doctoral candidate Faculty of Pharmacy
21 Kopra Jaakko Doctoral candidate Faculty of Pharmacy
22 Käenmäki Mikko Doctoral candidate Faculty of Pharmacy
23 Ossola Bernardino Doctoral candidate NIEHS, HIH, NC, USA
24 Paalanen Milla Doctoral candidate Faculty of Pharmacy
25 Peltonen Ida Doctoral candidate Faculty of Pharmacy
26 Piltonen Marjo Doctoral candidate Faculty of Pharmacy
27 Porokuokka (née Vilponen) Lauriina Doctoral candidate Faculty of Pharmacy and IB
28 Schendzielorz Nadia Doctoral candidate NIEHS, HIH, NC, USA
29 Talka Reeta Doctoral candidate Faculty of Pharmacy
30 Talman Virpi Doctoral candidate Faculty of Pharmacy
31 Voutilainen (née Kauppinen) Merja Doctoral candidate Faculty of Pharmacy
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Name of the RC’s responsible person: Tuominen, Raimo 
E-mail of the RC’s responsible person:   
Name and acronym of the participating RC: Pharmacology of Degenerative Brain Diseases, PDBD 
The RC’s research represents the following key focus area of UH: 2. Elämän perusrakenne – The basic 
structure of life 
Comments for selecting/not selecting the key focus area: “The basic structure of life” represents best our 
research in neuroscience, - in more specific terms - pharmacology of degenerative brain diseases.  Our 
research is internationally acknowledged and it adds to the basic knowledge of degenerative brain diseases 
and their future drug treatments. We employ sophisticated techniques such as basic molecular biology 
methods, gene modified animals, analysis of brain neurotransmitters (in conscious animals and in post 
mortem tissue) and animal models of diseases. Thus, our research aims at integrating knowledge on basic 
neuroscience to future treatments of degenerative brain diseases. In the University of Helsinki, 
neuroscience among other biomedical sciences has been very successful and highly ranked in international 
evaluations. 
 
 
 Description of the RC’s research focus, the quality of the RC’s research (incl. key research 
questions and results) and the scientific significance of the RC’s research for the research 
field(s).  
Focus. Our RC has a distinct research profile among other units of the Viikki Campus and the University 
of Helsinki. Main focus is on basic pharmacology of major degenerative brain diseases, especially that of 
Parkinson’s disease (PD), Alzheimer’s disease (AD), multiple sclerosis (MS) and addiction. Our dug 
related targets are: neurotrophic factos (NTFs), catechol-O-methyltransferase (COMT), protein kinase C 
(PKC), prolyl oligopeptidase (POP) and nicotine. Dopamine is a connecting link in Parkinson’s and 
addiction. In PD dopamine neurons of the s. nigra degenerate while in addiction dopamine neurons of 
ventral tegmental area are overactive. Our RC has focused on brain dopamine related 
neuropharmacology but also other targets such as aberrant protein processing have been important.                               
 
Quality of the RC's research. The quality of research is reflected by publication forums. These include 
top-journals such as Nature (IF 34.48) and PNAS (9,380) as well as high-ranking journals of neuroscience 
and neuropharmacology, like  J. Neurosci (7.178), Neurobiology of Aging (5.937), Br.J. Pharmacol 
(5.204), J  Med Chem (4.802), Mol. Pharmacol (4.531), Devel Biol (4.379), Biochem Pharmacol (4.25),  J 
Neurochem (3.999), and Eur J Pharm  Sci (2.608). RC has been involved in 3 EU-funded projects. There 
are international and national collaborative projects including those with laboratories in the USA, Russia, 
Estonia and UK. 
 
NTFs are natural proteins that promote survival and differentiation and contacts of neurons. Cerebral 
dopamine neurotrophic factor (CDNF) has been discovered in Helsinki University. We have shown that 
both CDNF and mesencephalic astrocyte-derived neurotrophic factor (MANF) have significant 
neuroprotective and neurorestorative effects against 6-hydroxydopamine (6-OHDA) induced 
degeneration of dopamine neurons in rats. In the same animal model neurodegeneration was 
prevented also by other trophic factors, i.e. GDNF and VEGF-C. Thus, the NTFs show therapeutic 
potential in the treatment of PD. In our addiction studies, gene modified mice with constantly active 
BACKGROUND INFORMATION 
1 FOCUS AND QUALITY OF RC'S RESEARCH (MAX. 8800 CHARACTERS WITH SPACES) 
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receptor for GDNF (MEN2B-mice) have very high concentrations of dopamine in the brain and show 
changes in addiction behaviour. 
          
COMT is an important target in PD. One of our PI (PTM) is associated with a development of a clinically 
used drug, entacapone, the only widely used COMT-inhibitor in the treatment of PD. COMT inactivates 
L-dopa and dopamine. It is a strictly intracellular enzyme, mainly in the cytoplasm and nucleus. COMT 
has two forms, soluble (S-COMT) and membrane bound (MB-COMT). Their importance in dopamine 
metabolism has been thoroughly studied by this RC. We have developed and fully used a large battery 
of tools: COMT-overexpressing or COMT-KO mice and mice lacking only S-COMT; peripheral and 
centrally acting COMT inhibitors; COMT antibodies and recombinant COMT proteins. We have shown 
that COMT is the major dictator of dopaminergic activity in the prefrontal cortex, in contrast to the 
striatum. In S-COMT deficient mice, MB-COMT substitutes about 50% of S-COMT, even in the periphery. 
COMT inhibition sensitizes to painful stimuli with an exception of neuropathic pain where it acts as an 
analgesic. Several important polymorphisms of the human COMT gene give a solid background for 
clinical applications 
  
PKC regulates amyloid precursor protein (APP) processing leading to decreased production of A  and 
increased production of nontoxic secreted amyloid precursor protein. PKC activators have shown 
therapeutic potential in in vivo animal models of AD. We have developed a novel class of synthetic C1 
domain ligands, which bind to PKC  and PKC  in submicromolar concentrations. Some of the 
compounds are able to activate PKC in cellular environment, and thus they are interesting lead 
molecules for AD-related drug development. PKC is also widely recognized cancer drug target and some 
of our compounds have antiproliferative effects in human cervical cancer cells. 
 
POP has multiple roles either by hydrolyzing <30-mer proline-containing peptides or by its newly 
discovered nonhydrolytic functions. Many novel physiological roles for POP have been uncovered by our 
RC. We have thoroughly characterized a distribution of POP protein inside the cells and in the body. 
Beneficial effects of our new POP inhibitors on memory, angiogenesis and -synuclein aggregates were 
clarified. POP seems to be a regulator of cellular differentiation and embryonic development. Our 
results indicate that POP may have even causative a role in Parkinson’s diseases via augmenting -
synuclein aggregation. POP is involved in the immune response with implications in autoimmune 
diseases such as MS and celiac disease. The specific POP-inhibitors, transgenic animals and disease 
models have been highly useful in the above studies. 
 
Addiction research. Nicotine and neuronal nicotinic acetylcholine receptors (nAChRs) have been in focus 
in addiction studies. Nicotine is one of the most addictive substances and we have shown that it 
sensitizes brain dopamine system. In line with this it is also active in an animal model of PD due to 
dopamine release in striatum. Chronic nicotine increased the number of its own receptors which were 
mostly intracellular and may serve as reservoir pool. Thus, we have proved up-regulation and 
internalization of the nAChRs at molecular level and in in vivo studies the effects of chronic nicotine 
exposure to behavioural and neurochemical effects of opioids. Currently we focus on nicotine-opioid 
interactions at the level of nAChRs. COMT is weakly and complicatedly associated with addiction. In 
COMT-KO-mice ethanol intake is increased but only in males. Heterozygous GDNF knockout mouse are 
more vulnerable to morphine-induced psychomotor sensitization than their wild-type littermates.  
 
The scientific significance.              
Our RC has shown that the NTFs (CDNF and MANF) have therapeutic potential in the treatment of PD. 
CDNF and MANF seem to possess a novel mechanism of action, which is different from that of GDNF. 
Our basic research on the role of GDNF in the regulation of midbrain dopaminergic neurons has 
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discovered some highly interesting and significant findings, e.g. related to addiction. COMT is the major 
determinant of the dopaminergic activity in the prefrontal cortex while in the striatum and nucleus 
accumbens the uptake of dopamine into the presynaptic terminals is the major player. Centrally acting 
COMT-inhibitors that modify prefrontal dopamine may have significant therapeutic applications in the 
future. POP is widely distributed in the body, including the brain. POP seems to have other functions 
beyond its proteolytic activity. If this holds true, it will open a new avenue of research on angiogenesis, 
inflammation and neurogenesis. PKC C1-domain targeted compounds are unique in that they can 
activate PKC. This is a prerequisite for the future PKC-targeted drugs used in AD. 
 Ways to strengthen the focus and improve the quality of the RC’s research. 
Our RC (“pharmacology of degenerative brain diseases”) has published major results in high impact 
international journals. After many original findings, like anti-parkinsonian effects of CDNF and MANF, 
they should focus on mechanistic studies, like on a role of various transmitters and intracellular 
messengers. The same holds true for POP project. After fundamental findings of general and 
developmental physiology and tissue, cellular and subcellular distribution of POP and its actions beyond 
hydrolysis, moving to animal models of PD and AD, MS and even cancer is warranted. Brain 
neurochemistry of gene modified mice using in vivo microdialysis of conscious animals to collect 
extracellular fluid in specific brain areas is a very strong method. Effects of drug treatments (e.g. CDNF-
and POP-proteins and POP-inhibitors) and gene therapy of Parkinson’s disease (e.g. by AAV-CDNF) and 
gene-therapy induced CNS-damage (e.g. by AAV- -synuclein) on brain function should be studied in 
detail. Correlation of neurochemistry and behaviour would be important. 
 
 
  How is doctoral training organised in the RC? Description of the RC’s principles for recruitment and 
selection of doctoral candidates, supervision of doctoral candidates, collaboration with faculties, 
departments/institutes, and potential graduate schools/doctoral programmes, good practises and 
quality assurance in doctoral training, and assuring good career perspectives for the doctoral 
candidates/fresh doctorates.  
Doctoral training has been significant part of the RC’s activities. Doctoral studies have been mainly 
organized by Graduate School in Pharmaceutical Research (GSPR, 
http://www.uku.fi/farmasia/tutkijakoulu/english/) which is funded by Academy of Finland (operational 
fund) and Ministry of Education and Culture (MEC, salaries of graduate school positions). The activity of 
GSPR is based on the research done in both of the higher pharmaceutical education units in Finland, 
Faculty of Pharmacy in the University of Helsinki and School of Pharmacy, Faculty of Health Sciences in 
the University of Eastern Finland, UEF (Kuopio campus). In addition, GSPR has close cooperation with 
Neuroscience Center and Institute of Biotechnology in Helsinki and AIV Institute in the UEF, Kuopio. 
Research and educational collaboration is practised with drug industry, inter/national authorities and 
scientific societies. Altogether there are about 150 students performing full time research and about 
100 students doing part-time doctoral training in GSPR.  About 70 supervisors have at least docent 
degree. 
 
PhD degrees by PDBD community. The PIs of the PDBD community have been involved in total of 13 PhD 
theses as supervisors or co-supervisors of which 9 have been done within the unit. One of the latter was 
awarded as the best thesis in pharmacology in Finland in the year 2009.  During the evaluation period, 
one PI (PTM) has supervised 6 dissertations that were finished and approved with distinction in his 
previous affiliation. The graduate school has been productive and has received top evaluations from the 
Academy of Finland. Director of this graduate school has been from our RC during the whole period of 
evaluation. 
2 PRACTISES AND QUALITY OF DOCTORAL TRAINING (MAX. 8800 CHARACTERS WITH SPACES) 
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Graduate School networks. Research groups have collaboration with several international and national 
networks (e.g. FinBioNet). The most important Finnish research training collaboration is FinPharmaNet 
network (started 2006-2007) which has additional 3 graduate schools focused in drug research. 
FinPharmaNet has two coordinators (also coordinating two graduate schools each) and a website 
(http://finpharmanet.utu.fi) which contains, for example, a detailed course calendar.  At 2012, these 
graduate schools will merge as one Doctoral program.  
 
Getting position at GSPR. MEC funded doctoral student positions are intended for four year full time 
research. GSPR has received increasing number of these positions from 11 (2005) up to 16 (2010). 
Doctoral students for MEC positions are recruited by open international call and about 20% of applicants 
have been accepted. The applications are evaluated by GSPR Board and positions are principally granted 
equally for each discipline and both universities. All doctoral students (also students paid by matching 
funds) who are registered in pharmacy units belong automatically to GSPR (unless they are members of 
other graduate schools), and they have similar benefits and duties as those paid by MEC.  At 
registration, preliminary research plan, study plan, approval of the head of pharmaceutical discipline are 
necessary, and 2-3 supervisors are named for each doctoral student. 
 
Postgraduate training. GSPR provides a training platform for all doctoral students, no matter where the 
salary originates, and controls their research training. The training is organized systematically, and 
several parts of it are obligatory. In the early phase of training, doctoral students have preliminary exam 
of their research discipline to make sure that students have enough background knowledge of the 
research field despite their basic academic degree. At about half-way of their doctoral training, students 
defend (without supervisor) their work and plan against 2-3 experts of the field. In these discussions the 
experts give constructive feedback to the student which increases the quality of the doctoral thesis and 
support students’ work.  
 
GSPR organises postgraduate level, scientific training courses mainly in Finland but there has been 
international courses as well. For example, Behavioral studies in drug discovery course has been  
organized 3 times, twice in the University of Tartu, and in 2008 Finnish– Estonian-German cooperation 
brought  together about 100 pharmacologist and neuroscientist of 11 nationalities. Course calendar is 
planned to cover several following years. Frequent courses are held at maximum 4 year intervals. Thus, 
students can compile their study plan already in the beginning of their doctoral training. GSPR organises, 
itself or as co-organiser, annually 10-25 courses. Almost all courses are in English and have international 
lecturers. Also experts from drug industry and authorities are used.  All courses are free. Some courses 
have laboratory work or demonstrations. Doctoral students participate in transferable skills courses in 
their host universities. 
 
FinPharmaNet network organises, in turn by each graduate school, an annual Joint meeting that 
contains lectures, student presentations, posters and social events for two days. In the meeting doctoral 
students have a possibility to get wide view of the whole drug research process. 
 
GSPR provides travel grants for participation in congresses and visits in the laboratories abroad. 
Especially international travel has been encouraged. GSPR co-organised Finnish Pharmacological 
Society’s Spring meeting in 2008 entitled Doctoral training internationally and in Finland. This occasion 
showed that European doctoral training is still far from uniform and that Finnish graduate school model 
is a good for doctoral students. 
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Annually altogether 20-30 PhD degrees from the GSPR are approved by the two Universities in Finland. 
All (= 100%) of doctors are employed after their graduation, most of them by universities in Finland and 
abroad, but quite many also by international or national drug industry. 
  
Administration. GSPR Board has representatives from both universities and from several disciplines. 
GSPR administration has broad pharmaceutical background. Summaries of the GSPR Board decisions are 
published in the web site to inform and guarantee open decision-making and equal pharmaceutical 
research training in Finland. Preliminary examination, defense of research plan and close collaboration 
with pharmaceutical faculties guarantees doctoral student follow-up. Courses are planned several years 
ahead with budget and program to assist study planning. Feedback is collected of the GSPR courses to 
get participant and lecturer opinions. 
 RC’s strengths and challenges related to the practises and quality of doctoral training, and the actions 
planned for their development. 
We interpret that the doctoral training has been nearly optimally organized in GSPR,  no matter how the 
students are financed. All enter the school, assuming that the registration requirements are filled, and 
after that all have similar duties and benefits. This has been a very wise policy since the number of 
students paid by Academy of Finland (16) is a fraction of other students (250). When selecting those 16, 
multidisciplinary nature of pharmacy has led to special approach where the main competition is inside 
each discipline. Initial examination and defence of the research plan are excellent obligatory 
requirements. 
 
The main challenge will be merge of the four FinPharmaNet graduate schools to one doctoral program. 
A co-operation has been practised many years and the new leader of the Drug Research Doctoral 
Program will be from our RC (RKT), and the home of the program will be Helsinki University. However, 
selection of the students (paid by MEC) will be a major task. A quality handbook compilation for FPDP is 
in progress to harmonize variable practices of the previous 4 schools. 
 
 
 Description of how the RC interacts with and contributes to the society (collaboration with public, 
private and/or 3rd sector).  
The PIs of the RC have given expert opinions related to new drugs under development or under 
marketing authorisation process. These statements and opinions have been asked by private sector 
(pharmaceutical companies) as well as public authorities (Finnish Medicinal Agency, FIMEA). The RC has 
given statements and comments related to legislation issues in health sector. One of the PIs (RKT) of the 
RC has given a public presentation on the effect of nicotine to members of parliament in connection to 
availability of nicotine replacement products in retail trade, i.e. outside pharmacies. Another PI (PTM) 
has been in a board of directors of 2 small companies. 
 
Research done in the RC is important for the society since ageing population with increased prevalence 
of degenerative brain diseases is one of the major challenges world-wide. Drug therapies of Alzheimer’s 
disease and Parkinson’s disease have not really developed much during the past ten years and there is a 
large unmet need for better therapies. Basic research is the key to new applications. Addictions 
represent a big health problem in the society. All addictions, i.e addiction to food, alcohol, gambling, 
drugs etc. share the same neurobiological basis. Although not all addictions may be cured by medicines, 
a big group of people would benefit from effective medicines. 
 
3 SOCIETAL IMPACT OF RESEARCH AND DOCTORAL TRAINING (MAX. 4400 CHARACTERS WITH SPACES) 
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Doctors graduated from this RC have been employed by both private and public sectors. These include 
universities (n=5; one post-doc in the US, one in Europe, three in the University of Helsinki), research 
institutes (n=1; one post-doc in the US); pharmaceutical industry (n=2; one post doc in Europe, one 
senior researcher in Finland), civil service departments (n=2; two officers). Four of the total number 
(n=14) have been employed by pharmacies. 
 
The PIs of the RC have been active towards the Finnish Parkinson Society by giving lectures in 
Movement Disorder Club meetings and writing article to the Journal of the Finnish Parkinson patient 
organization. Several interviews to various magazines have been given and there are a few appearances 
of the PI’s in TV. 
 Ways to strengthen the societal impact of the RC’s research and doctoral training. 
The RC should inform stakeholders and general public about their research, when it is reasonable. This 
would also increase level of knowledge on basic science among decision makers, which would be 
beneficial for the future funding of the research. Interaction with politicians even may be of significance. 
More interaction with pharmaceutical industry in drug research would be, in an optimal case, a win-win 
situation. Being a member of the board of directors of SMS companies would serve the social impact as 
well. In doctoral training the RC should take into account the need for a broader understanding of 
medicines which would give better prerequisite for the various positions where a pharmacologist will 
make his/her career. 
 
 
 
 Description of the RC’s research collaborations and joint doctoral training activities and how the RC 
has promoted researcher mobility.  
International collaborations can be divided in two major categories (1) EU-projects within FP6 and FP7 
and (2) other more bilateral collaborations between specific laboratories. The Pro-KinaseResearch 
Consortium (www.proteinkinase-research.org) was coordinated by the RC during 2004-2009. Altogether 
25 Partners from 12 countries (Austria, Finland, France, Germany, Holland, Hugary, Israel, Italy, Norway, 
Switzerland, Russia and U.K.) were involved. The research focus was on new drug candidates targeting 
protein kinases. Research collaboration continues. NeuroPro consortium (www.neuropro.eu) is doing 
research on role of POP as drug target in neurodegeneration. In this FP7 project there are 7 (Belgium, 
U.K., Germany, Estonia, Hungary, Finland) partners. The scientific coordinator is from our RC (A. Garcia-
Horsman). A related collaboration with University of Valencia, Spain (Dr. Felipo) as well as with the Paul-
Flechsig-Institute for Brain Research (Dr. Rossner) in Leipzig has been setup. We have coordinated an 
Addiction Research Consortium funded by the Academy of Finland. Within this project collaboration 
with Pavlov Medical University in St. Petersburg (prof. E. Zvartau) was successful. In COMT-research a 
long-term collaboration with Rockefeller Center and subsequently Columbia University, College of 
Physicians & Surgeons, and with prof. Noburo Hiroi in Albert Einstein Institute, New York, USA, has 
continued. A new collaboration with Elizabet Tunbridge and Trevor Sharp has started when Mikko 
Käenmäki (MSc) began his research visit to Oxford in the Fall of 2010.  
 
National collaboration with the University of Eastern Finland (Kuopio), Department of Pharmacology and 
Toxicology, has been active particularly since it was the previous affiliation of one PI (PTM). These 
studies have mainly included POP and COMT research. Six PhD degrees have been finished and two are 
still ongoing. Our RC had collaboration with the University of Tampere within the ELVIRA program 
(coordinator prof. M. Mäki, Tampere) financed by the Academy of Finland during 2007-2010. The topic 
was celiac disease, its genetic background, degradation of gliadins in foods, before eating, and in the 
4 INTERNATIONAL AND NATIONAL (INCL. INTERSECTORAL) RESEARCH COLLABORATION AND RESEARCHER 
MOBILITY (MAX. 4400 CHARACTERS WITH SPACES) 
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body after eating. Also with Tampere University (prof. Moilanen) we had collaboration within the PKC-
project.  
 
Intersectoral collaboration with the National Institute for Health and Welfare, Helsinki (THL, prof. 
Kiianmaa, doc. Hyytiä) in addiction research has continued for years. 
 
Within our University the collaboration with Institute of Biotechnology, Brain Research Center and 
Biomedicum Helsinki have been instrumental. These cooperations have been substantiated with several 
common PhD projects. 
 
Researcher mobility has been active in both pre- and post-doctoral level. Two of our PhD students spend 
more than one year in NIEHS, NIH, NC, USA studying effects of amantadine in animal models of PD and 
at the present time one doctoral student is working in the University of Oxford, U.K. Post-doctoral 
training has been done or is going on in several countries (n= 6); one in Switzerland, one in Belgium, one 
in the Netherlands, and three in the USA. We have hosted visitors from abroad: two from Spain, one 
from Germany, Italy and The Netherlands, and two short-term visitors from Russia. 
 RC’s strengths and challenges related to research collaboration and researcher mobility, and the 
actions planned for their development. 
The PDBD consortium has good connections to European and US scientists. At the present we are 
involved in two European collaborations (EraNet Neuron project on CDNF and NeuroPro project on POP) 
an in one US collaboration (MJFF funded project on CDNF coordinated by acad.prof. Saarma, University 
of Helsinki). Our RC has been the most productive group in the NEUROPRO consortium and the 
challenge is to further foster and expand the research.  Accordingly, our strategy is to increase research 
collaboration in the frame of EU funded FPs and due to our good experiences in the past. Post-doctoral 
fellows have opened new contacts especially in the US and these should be used in the future to build 
up networks with scientists in the US.  We are quite regularly contacted by foreign students who would 
like obtain a graduate school position in our RC. However, at the present time and probably also in the 
near future we have only limited resources for this. The practically only funding source is the Center for 
International Mobility (CIMO), but these grants are only for a limited period of time. 
 
 
 Description of the operational conditions in the RC’s research environment (e.g. research 
infrastructure, balance between research and teaching duties).  
Research environment and infra. The overall research conditions have been good. During this period, we 
have been able to upgrade our experimental neurosurgery unit called Stereotaxic Center to meet very 
high standards. Within the Center we also have a permit to make gene transfers to mice and rats. This 
facility is available to other neuroscientists of the University as well. We have also upgraded our HPLC 
systems (n=5) used in the analysis of neurotransmitters and their metabolites in brain tissue and 
extracellular fluid. The latter samples are collected from conscious animals (rats and mice) by using 
microdialysis technique. We have appropriate cell culture facilities of safety level 2 (for viral 
transfections) and both standard light and fluorescence microscopes. In our molecular biology 
laboratory we are able to make cloning and expression of proteins and we also have a PCR and qPCR for 
RNA measurements. The behavioural pharmacology equipment have been partially renewed, especially 
the turning behaviour apparatus used in Parkinson research (two units with 8 chambers each). 
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We have access to the core facilities of the Viikki Campus and Meilahti Campus. Biocentrum Helsinki and 
Biocentrum Finland provide many of these core-units and especially the Light Microscopy Unit and 
equipment within Brain Research Center here in Viikki have been of paramount importance for our 
research. Very recently a top-of-the-line SPECT/CT imaging system with resolution of less than one 
millimeter was purchased to our faculty and is at our disposal. This imaging system allows us to perform 
sophisticated visualization of drug effects in the brains of living animals. 
 
Lack of appropriate animal facilities in our campus (Viikki) has been a major drawback. With the 
permission of the Chief Veterinarian of the County Administrative Board we have had the possibility to 
keep animals in specific rooms inside our Division. Also all surgical operations as well as experiments 
have been done at the Division. We have some shortage of office space and two laboratories have been 
converted to offices hosting six persons each. 
 
During the last three years we have built a quality assurance system for research and teaching. We have 
adopted standard operation procedures (SOPs) for more than 15 processes and to about 25 
instruments. 
 
Teaching. Our teaching load is heavy. We teach 28 % of the study points (ECTS) of the faculty of 
pharmacy. During 2005-2010 we supervised 27% (69 out of 258) of master thesis works done in the 
faculty. During the same period of time we produced 10 PhD thesis work, which is 13% of the 
production by the whole faculty. These figures reflect the position of pharmacology in the curriculum of 
the faculty of pharmacy. The RC is proud to tell about the willingness of all researchers and staff 
members to teach pharmacology. In addition to persons paid by university budget funding, also all 
researchers paid by external funding participate teaching with a certain work share (about 5% of their 
hours). 
 RC’s strengths and challenges related to operational conditions, and the actions planned for their 
development. 
The ultimate strengths of our RC are: refined skills in major types of neuropharmacological tools, an up-
to-date stereotaxic unit and access to sophisticated instruments in the core units and other units of 
Viikki Biocentrum. 
 
The major challenge is to get a new rodent house where all of the animal operations  will be transferred. 
We support the building process in all possible ways, and fortunately the project is now in a planning 
phase and the renovated unit will be available at the end of 2012. A volume of teaching of toxicology by 
RC is very modest, and this should be improved by number of means, including a Swedish-speaking 
professorship in toxicology. 
 
 
 
 Description of the execution and processes of leadership in the RC, how the management-related 
responsibilities and roles are distributed in the RC and how the leadership- and management-related 
processes support high quality research, collaboration between principal investigators and other 
researchers in the RC, the RC’s research focus and strengthening of the RC’s know-how.  
In our RC we have 2 full professors, 3 university lecturers, 1 post doctoral and 3 doctoral students who 
are paid by the University. In addition we have 3 post-doctoral researchers, one graduate school 
coordinator and 9 doctoral student paid by external funding. Six out of the 9 senior scientists (including 
post-docs) have a principal investigator (PI) status. Leadership of the RC is divided into faculty 
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administration and research leadership. These two are partially overlapping. Head of the Division (RKT) 
is responsible for most of the faculty administration including hiring personnel, use of budget funds and 
organizing undergraduate teaching as well as studies related to doctoral studies. He is the leader of 
research on PKC, addiction studies and in collaboration with the other professor (PTM) leads the 
Neurotrophic factors in PD – project. The other full professor (PTM) is the leader of COMT and POP 
projects and he also is leader of graduate school courses. The University lecturers have a rather heavy 
teaching load, but they also have a leadership role as thesis work supervisors or co-supervisors in 
projects mentioned above. Each of them has a primary role; one is doing nicotine pharmacology, one is 
specialist in brain neurochemistry and one is doing gene-delivery and apoptosis related research.  
 
The post-doctoral researchers are responsible for their research projects and they also hire PhD 
students to be trained in their projects. They have appropriate lab space and all available infra structure 
at their disposal for executing their research. One of the post-docs has been working in a brain 
neurochemistry project and the three others are in the POP-project.  
 
The two professors have been in charge for the most part of the large grant applications such as those 
submitted to Academy of Finland, Sigrid Juselius Foundation, Michael J. Fox foundation and EU. The 
University lecturers have been able to get external funding for their research and they are responsible 
for the research done by their grants. The post-doctoral researchers have their own grants (EU FP7, 
Finnish Cultural Foundation, Erkko Foundation, the Academy of Finland) and they are responsible for 
their research projects and use of the funds and reporting.  
 
We focus on neuropharmacology and neuroscience. Therefore the methods used in the research 
projects are overlapping in most parts. This is strength as the researchers can share their expertise in 
the lab. Our quality assurance system forms a solid basis for the technical quality of research. The 
research projects have regular meetings and usually one or both of the professors participate. Once a 
week there is a research meeting of the whole Division and once a month we have a Division meeting 
(mostly administrative issues but also practical issues on laboratory work). 
 
Our research management system supports academic leadership. Taking into account the fact that we 
have a rather heavy teaching load, the distribution of leadership and responsibilities among the senior 
scientists is the best way to accomplish high quality research. Together with common nominator of 
research, the neurodegenerative diseases, and shared methods and shared responsibilities this 
management structure supports the focus of research and know-how. 
 RC’s strengths and challenges related to leadership and management, and the actions planned for 
developing the processes. 
We cannot identify any major problems in administration of RC. All personnel are able to work together 
and there is nothing that could not be discussed. We have also obtained extra resources, although 
minor, for teaching, and we have excellent candidates who have applied for the newly established 
tenure tract. It is also very positive that there is time for research on which even about 50% of the 
resources can be used. 
 
The major challenges are short-lasting recruitments owing to short financing terms of the private grants. 
Also, positions for  Swedish-speaking teaching personnel are lacking and only basic skills can be used. 
Steps have been taken to support a new Swedish-speaking professorship in toxicology. 
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 Listing of the RCs external competitive funding, where: 
- the funding decisions have been made during 1.1.2005-31.12.2010, and 
- the administrator of the funding is/has been the University of Helsinki 
 
 Academy of Finland (AF) - total amount of funding (in euros) AF has decided to allocate to the RC 
members during 1.1.2005-31.12.2010: 1070000 
 
 Finnish Funding Agency for Technology and Innovation (TEKES) - total amount of funding (in euros) 
TEKES has decided to allocate to the RC members during 1.1.2005-31.12.2010: 0 
 
 European Union (EU) - total amount of funding (in euros) EU has decided to allocate to the RC members 
during 1.1.2005-31.12.2010: 1705000 
 
 European Research Council (ERC) - total amount of funding (in euros) ERC has decided to allocate to the 
RC members during 1.1.2005-31.12.2010: 0 
 
 International and national foundations – names of international and national foundations which have 
decided to allocate funding to the RC members during 1.1.2005-31.12.2010, and the amount of their 
funding (in euros).  
- names of the foundations: Michael J. Fox Foundation for Parkinson’s disease, USA 
- Sigrid Juselius Foundation, Finland 
- Finnish Cultural Foundation 
- Päivikki ja Sakari Sohlbergs Foundation, Finland 
- Finnish Parkinson Foundation 
- Research Foundation of the University of Helsinki, Finland 
- Orion-Farmos Research Foundation, Finland 
- Ella and Georg Ehrnrooth Foundation, Finland 
- Emil Aaltonen Foundation, Finland 
- Finnish Pharmaceutical Association 
- total amount of funding (in euros) from the above-mentioned foundations: 866000 
 
 Other international funding - names of other international funding organizations which have decided to 
allocate funding to the RC members during 1.1.2005-31.12.2010, and the amount of their funding (in 
euros). 
- names of the funding organizations: GGL Pharmaceutical Ltd., China 
- total amount of funding (in euros) from the above-mentioned funding organizations: 87,000 euro 
 
 Other national funding (incl. EVO funding and Ministry of Education and Culture funded doctoral 
programme positions) - names of other national funding organizations which have decided to allocate 
funding to the RC members during 1.1.2005-31.12.2010, and the amount of their funding (in euros). 
- names of the funding organizations:  
- total amount of funding (in euros) from the above-mentioned funding organizations:  
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 Description of the RC’s future perspectives in respect to research and doctoral training. 
Personnel.  Only 40% of RC staff is paid by Helsinki University (2 professors, 3 lecturers, 1 post-docs and 
3 doctoral students). RC has 3 post-docs and 9 doctoral student paid by external funding.  
 
During 2012, one professor will retire and it is essential to keep the position in our RC. Since the 
professor both teaches (see also Item 5, teaching) and studies, the person should have teaching 
experience and the area of research would preferably be neuroscience. Funding of 2 post-docs should 
be renewed depending on external funds (see strategy below). There is an enormous need to get post-
doc positions be more solidly funded (e.g., 5-year terms). Our RC competes for 1 tenure track position in 
the faculty. We have 2 post-docs returning from the USA in 2011 – 2013. We can provide space and 
equipment to them if they are able get finances for their salaries and research. 
 
The mainstay in our research strategy is pharmacology of degenerative brain diseases, especially 
research on neurotrophic factors (CDNF, MANF and GDNF), COMT and POP. We have a good knowledge 
and publication record in these subjects. Our expertise in animal models of brain diseases and the 
research infra- structure within our unit and the Viikki campus is strong and forms a solid basis for this 
strategy. Methods/infra include gene modified animals, disease models, Stereotaxic Center, brain 
neurochemistry, immunohistochemistry and SPECT/CT imaging. Research collaboration with Institute of 
Biotechnology and Neuroscience Center as well as “in-house” with the other units in our faculty will 
continue and find new forms. When a new animal facility has been built, the division-level problems 
concerning animal care and allergy problems should be resolved. 
 
Two drug discovery projects, POP and PKC as novel drug targets, will be continued to animal studies. We 
have relevant novel molecules in the category “hit-to-lead” in both and proof-of-concept type 
experiments are needed. In both cases, drug targeting to the CNS is a challenge and collaboration with 
the CDR (Center for Drug Discovery) is needed. We will also need to expand collaboration with 
pharmaceutical industry within a few years. Our RC is not planning to start spin-off companies. 
 
Funding. The PDBD RC has been successful in fund raising, and also in the future we are crucially 
dependent on competitive research funding. Our strategy is to apply grants from all national and 
international funding bodies. The quality of research done in RC has been at a high international level, 
and the same standard should be kept. The social impact of neuroscience is prominent as such. The 
funding sources include Academy of Finland and many foundations like Sigrid Juselius foundation and 
international sources such as EU FP7 and the forthcoming FPs. These applications will be based on our 
former and prevailing research networks, but applications will be sent also to ERC, Wellcome Trust and 
NIH. Partners are available from familiar European networks. International sources are very competitive 
but necessary since the Finnish research funding may collapse due to the new full cost model. This 
system has been implemented with no increase in budgets of the funding bodies. In the case our 
strategy relying on international funding fails, it would cause serious problems. 
 
Doctoral training. Starting from 2012, Graduate School of Pharmaceutical Research (GSPR) will be one of 
the 4 sections of a new doctoral program, FDPD, that covers all areas of drug research. The disciplines 
include molecular, modelling of syntheses and pharmacokinetic, virtual screening, synthesis of organic 
compounds, analytical methods, new drug research methods, pharmaceutical technology, 
pharmacology, clinical pharmacology and toxicology. University of Helsinki will host the program and the 
head of the RC (RKT) will be the first director. GSPR has now 16 graduate school positions and in the 
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new program the number should remain the same or even increase. Within our RC, we have had 1-2 
paid graduate school positions from the GSPR. However, all our PhD students (now12) are affiliated to 
the program and implement the structure of GSPR in their studies. During the period 2011-2013 we 
expect that in our RC will generate at least 9 PhD degrees. 
 
 
 
How RC members contributed ? 
 
RKT and PTM collected the material from all PI’s and wrote the initial draft of Stage 2 evaluation report. 
All PI’s commented, proofread, and amended the draft. RKT wrote the final version with all PI’s 
approval. 
 
Abbreviations:  
RKT: prof. Raimo K. Tuominen, MD, PhD, Head of the Division of Pharmacology and Toxicology and 
Coordinator and PI of the PDBD Research Community 
PTM: prof. Pekka T. Männistö, MD, PhD, Professor of Pharmacology and Drug Discovery, Division of 
Pharmacology and Toxicology, PI of the PDBD Research Community. 
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1 Analysis of publications 
 
- Associated person is one of Pekka Männistö ,  Raimo Tuominen ,  Timo Petteri Piepponen , 
 Atso Raasmaja , Outi Salminen ,  Tanja Kivinummi ,  
Elina Ekokoski ,  Juan Arturo Garcia Horsman ,  Timo Tapio Myöhänen ,  Ilkka Reenilä , 
 Mikko Airavaara ,  Sanna Janhunen, Jelena Mijatovic ,  Jukka Pakkanen , 
 Anne Emilia Tammimäki ,  Jofre Tenorio-Laranga ,  Susanne Bäck , 
 ,  Oleg Kambur ,  Jaakko Kopra ,  Mikko Käenmäki , 
 Bernardino Ossola ,  Iida Peltonen ,  Marjo Hannele Piltonen , 
 Lauriina Porokuokka , Nadia Schendzielorz ,  Reeta Talka , 
 Virpi Talman , Merja Voutilainen ,  
 
Publication year 
Publication type 2005 2006 2007 2008 2009 2010 
Total Count 2005 - 
2010 
A1 Refereed journal article 17 16 19 19 25 20 116 
A2 Review in scientific journal     1 4 5 
A3 Contribution to book/other compilations (refereed)   14  1  15 
A4 Article in conference publication (refereed)   1 1   2 
B1 Unrefereed journal article 3 3 2 2 2  12 
B3 Unrefereed article in conference proceedings    2   2 
D1 Article in professional journal      2 2 
D3 Article in professional conference proceedings      1 1 
D4 Published development or research report     1  1 
E1 Popular article, newspaper article 3   1   4 
 
 
 
PDBD/Tuominen 
 
 
2 
 
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC TUHAT COMPILATIONS OF PUBLICATIONS DATA 2005-2010 
 
 
2 Listing of publications 
A1 Refereed journal article 
2005 
Forsberg, MM, Huotari, M, Savolainen, J, Mannisto, PT  2005, 'The role of physicochemical properties of entacapone and tolcapone on 
their efficacy during local intrastriatal administration', European Journal of Pharmaceutical Sciences, vol 24, pp. 503-511. 
Janhunen, S, Tuominen, RK, Ahtee, L 2005, 'Comparison of the effects of nicotine and epibatidine given in combination with 
nomifensine on rotational behaviour in rats', Neuroscience Letters, vol 381, no. 3, pp. 314-9. 
Janhunen, S, Mielikäinen, P, Paldanius, P, Tuominen, RK, Ahtee, L, Kaakkola, S 2005, 'The effect of nicotine in combination with 
various dopaminergic drugs on nigrostriatal dopamine in rats', Naunyn-Schmiedeberg's Archives of Pharmacology, vol 371, no. 6, 
pp. 480-491. 
Janhunen, S, Tuominen, RK, Piepponen, TP, Ahtee, L 2005, 'Nicotine and epibatidine alter differently nomifensine-elevated dopamine 
output in the rat dorsal and ventral striatum', European Journal of Pharmacology, vol 511, no. 2-3, pp. 143-50. 
Janhunen, S, Linnervuo, A, Svensk, M, Ahtee, L 2005, 'Effects of nicotine and epibatidine on locomotor activity and conditioned place 
preference in rats', Pharmacology, Biochemistry and Behavior. 
Jarho, E, Wallen, EAA, Christiaans, J, Forsberg, M, Venäläinen, J, Männistö, PT, Gynther, J, Poso, A 2005, 'Dicarboxylic acid azacycle 
L-prolyl-pyrrolidine amides as prolyl oligopeptidase inhibitors and three-dimensional quantitative structure-activity relationship of the 
enzyme-inhibitor interactions', Journal of Medicinal Chemistry, vol 48, no. 15, pp. 4772-4782. 
Manakova, S, Singh, A, Kääriäinen, T, Taari, H, Kulkarni, S, Männistö, PT 2005, 'Failure of FK506 (tacrolimus) to alleviate 
apomorphine-induced circling in rat Parkinson model in spite of some cytoprotective effects in SH-SY5Y dopaminergic cells',  Brain 
Research : international multidisciplinary journal devoted to fundamental research in the brain sciences, vol 1038, no. 1, pp. 83-
91. 
Nissinen, E, Nissinen, H, Larjonmaa, H, Väänänen, A, Helkamaa, T, Reenilä, I, Rauhala, P 2005, 'The COMT inhibitor, entacapone, 
reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats', Journal of Neural Transmission, vol 112, no. 9, 
pp. 1213-1221. 
Nuutinen, S, Ahtee, L, Tuominen, RK 2005, 'Time and brain region specific up-regulation of low affinity neuronal nicotinic receptors 
during chronic nicotine administration in mice', European Journal of Pharmacology, vol 515, no. 1-3, pp. 83-9. 
Pakkanen, J, Jokitalo, E, Tuominen, RK 2005, 'Up-regulation of ß2 and 7 subunit containing nicotinic acetylcholine receptors in mouse 
striatum at cellular level', European Journal of Neuroscience, vol 21, no. 10, pp. 2681-91. 
Pakkanen, J, Nousiainen, H, Yli-Kauhaluoma, J, Kylänlahti, I, Möykkynen, T, Korpi, ER, Peng, J, Lukas, R, Ahtee, L, Tuominen, R 2005, 
'Methadone increases intracellular calcium in SH-SY5Y and SH-EP1-h[alpha]7 cells by activating neuronal nicotinic acetylcholine 
receptors', Journal of Neurochemistry, vol 94, no. 5, pp. 1329-1341. 
Salminen, O, Whiteaker, P, Grady, S, Collins, A, McIntosh, JM, Marks, M 2005, 'The subunit composition and pharmacology of -
Conotoxin MII-binding nicotinic acetylcholine receptors studied by a novel membrane-binding assay', Neuropharmacology. 
Sandler, C, Ekokoski, E, Lindstedt, KA, Vainio, PJ, Finel, M, Sorsa, T, Kovanen, PT, Golub, L, Eklund, KK, Eklund, K 2005, 'Chemically 
modified tetracycline (CMT)-3 inhibits histamine release and cytokine production in mast cells: possible involvement of protein kinase C',  
Inflammation Research, vol 54, pp. 304-312. 
Seeman, P, Weinshenker, D, Quirion, R, Srivastava, IAK, Bhardwaj, SK, Grandy, DK, Premont, RT, Sotnikova, TD, Boksa, P, El-
Ghundi, M, O'Dowd, BF, George, SR, Perreault, ML, Mannisto, PT, Robinson, S, Palmiter, RD, Tallerico, T  2005, 'Dopamine 
supersensitivity correlates with D2(High) states, implying many paths to psychosis', Proceedings of the National Academy of 
Sciences of the United States of America, vol 102, pp. 3513-3518. 
Uutela, P, Reinilä, R, Piepponen, P, Ketola, RA, Kostiainen, R, Ketola, R 2005, 'Analysis of acetylcholine and choline in microdialysis 
samples by liquid chromatography/tandem mass spectrometry', Rapid Communications in Mass Spectrometry, vol 19, no. 20, pp. 
2950-2956. 
Venäläinen, JI, Wallen, EAA, Poso, A, García-Horsman, JA, Männistö, P 2005, 'Synthesis and characterization of the novel fluorescent 
prolyl oligopeptidase inhibitor 4-fluoresceinthiocarbamoyl-6-aminocaproyl-L-prolyl-2(S)-(hydroxy-acetyl)pyrrolidine',  Journal of 
Medicinal Chemistry, vol 48, no. 23, pp. 7093-7095. 
Yavich, L, Oksman, M, Tanila, H, Kerokoski, P, Hiltunen, M, van Groen, T, Puoliväli, J, Männistö, PT, Garcia Horsman, JA, MacDonald, 
E, Beyreuther, K, Hartmann, T, Jakala, P 2005, 'Locomotor activity and evoked dopamine release are reduced in mice overexpressing 
A30P-mutated human alpha-synuclein', Neurobiology of Disease, vol 20, no. 2, pp. 303-313. 
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Abin -Carriquiry, JA, Voutilainen, M, Barik, J, Cassels, B, Iturriaga-Vasquez, P, Bermudez, I, Durand, C, Dajas, F, Wonnacott, S  2006, 
'C3-halogenation of cytisine generates potent and efficacious nicotinic receptor agonists', European Journal of Pharmacology. 
Afrasiabi, E, Blom, T, Ekokoski, E, Tuominen, RK, Törnquist, K 2006, 'Sphingosylphosphorylcholine enhances calcium entry in thyroid 
FRO cells by a mechanism dependent on protein kinase C', Cellular Signalling, vol 18, no. 10, pp. 1671-8. 
Airavaara, M, Mijatovic, J, Vihavainen, T, Piepponen, P, Saarma, M, Ahtee, L 2006, 'In heterozygous GDNF knockout mice the 
response of striatal dopaminergic system to acute morphine is altered', Synapse (New York), vol 59, no. 6, pp. 321-329. 
Jarho, E, Venäläinen, J, Juntunen, J, Yli-kokko, AL, Vepsäläinen, J, Christiaans, J, Forsberg, M, Järvinen, T, Männistö, PT, Wallen, 
EAA 2006, 'An introduction of a pyridine group into the structure of prolyl oligopeptidase inhibitors',  Bioorganic & Medicinal Chemistry 
Letters, vol 16, no. 21, pp. 5590-5593. 
Myöhänen, T, Venäläinen, J, Garcia Horsman, JA, Miettinen, R, Mannisto, P 2006, 'Distribution of prolyl oligopeptidase in the rat brain', 
Acta Pharmacologica Sinica, vol 27, pp. 252-252. 
Nuutinen, S, Ekokoski, E, Lahdensuo, E, Tuominen, RK 2006, 'Nicotine-induced upregulation of human neuronal nicotinic 7-receptors is 
potentiated by modulation of cAMP and PKC in SH-EP1-h7 cells', European Journal of Pharmacology, vol 544, no. 1-3, pp. 21-30. 
Pakkanen, JS, Stenfors, J, Jokitalo, E, Tuominen, RK 2006, 'Effect of chronic nicotine treatment on localization of neuronal nicotinic 
acetylcholine receptors at cellular level', Synapse (New York), vol 59, no. 7, pp. 383-393. 
Puttonen, K, Lehtonen, S, Raasmaja, A, Männistö, PT 2006, 'A prolyl oligopeptidase inhibitor, Z-Pro-Prolinal, inhibits glyceraldehyde-3-
phosphate dehydrogenase translocation and production of reactive oxygen species in CV1-P cells exposed to 6-hydroxydopamine', 
Toxicology in Vitro, vol 20, no. 8, pp. 1446-1454. 
Raasmaja, A, York, D 2006, 'Pharmacological characterization of - and ß-adrenergic synergism of 5DII activity in rat brown adipocytes',  
Archives of Physiology and Biochemistry. 
Salminen, O 2006, 'Nikotiinireseptorit aivojen dopaminergisissä hermopäätteissä: post doc tutkimusta Coloradon yliopistossa USA:ssa',  
Dosis, vol 22, no. 3, pp. 249-258. 
Salonen, T, Sareila, O, Jalonen, U, Kankaanranta, H, Tuominen, RK, Moilanen, E  2006, 'Inhibition of classical PKC isoenzymes 
downregulates STAT1 activation and iNOS expression in LPS-treated murine J774 macrophages', British Journal of Pharmacology, 
vol 147, no. 7, pp. 790-9. 
Tammimäki, A, Pietilä, K, Raattamaa, H, Ahtee, L 2006, 'Effect of quinpirole on striatal dopamine release and locomotor activity in 
nicotine-treated mice', European Journal of Pharmacology. 
Venäläinen, J, García-Horsman, JA, Forsberg, M, Jalkanen, A, Wallen, EAA, Jarho, E, Christiaans, J, Gynther, J, Männistö, PT  2006, 
'Binding kinetics and duration of in vivo action of novel prolyl oligopeptidase inhibitors', Biochemical Pharmacology, vol 71, no. 5, pp. 
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Vihavainen, T, Mijatovic, J, Piepponen, TP, Tuominen, RK, Ahtee, L 2006, 'Effect of morphine on locomotor activity and striatal 
monoamine metabolism in nicotine-withdrawn mice', Behavioural Brain Research, vol 173, no. 1, pp. 85-93. 
Väänänen, A, Rauhala, P, Tuominen, RK, Liesi, P 2006, 'KDI tripeptide of 1 laminin protects rat dopaminergic neurons from 6-OHDA 
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Biochemistry, vol 397, no. 2, pp. 266-266. 
Tenorio-Laranga, J, Coret-Ferrer, F, Casanova-Estruch, B, Burgal, M, García-Horsman, J  2010, 'Prolyl oligopeptidase is inhibited in 
relapsing-remitting multiple sclerosis', Journal of Neuroinflammation, vol 7, pp. art. 23. 
Zhao-Shea, R, Cohen, BN, Just, H, McClure-Begley, T, Whiteaker, P, Grady, SR, Salminen, O, Gardner, PD, Lester, HA, Tapper, AR  
2010, 'Dopamine D-2-receptor activation elicits akinesia, rigidity, catalepsy, and tremor in mice expressing hypersensitive 4 nicotinic 
receptors via a cholinergic-dependent mechanism', FASEB Journal, vol 24, no. 1, pp. 49-57. 
A2 Review in scientific journal 
2009 
Ossola, B, Kääriäinen, T, Männistö, P 2009, 'The multiple faces of quercetin in neuroprotection', Expert Opinion on Drug Safety, vol 8, 
no. 4, pp. 397-409. 
2010 
Kambur, O, Männistö, P 2010, 'Catechol-O-methyltransferase and pain', International Review of Neurobiology, vol 95, pp. 227-279. 
Myöhänen, TT, Männistö, P 2010, 'Distribution and functions of catechol-O-methyltransferase proteins: do recent findings change the 
picture?', International Review of Neurobiology, vol 95, pp. 29-47. 
Männistö, P, Tammimäki, AE 2010, 'Are genetic variants of COMT associated with addiction?',  Pharmacogenetics and Genomics, vol 
20, no. 12, pp. 717-741. 
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Nissinen, E, Männistö, P 2010, 'Biochemistry and pharmacology of catechol-O-methyltransferase inhibitors', International Review of 
Neurobiology, vol 95, pp. 73-118. 
A3 Contribution to book/other compilations (refereed) 
2007 
Männistö, PT, Tuominen, RK 2007, 'Virustautien hoitoon tarkoitetut mikroblääkkeet', Farmakologia ja toksikologia, Medicina, Kuopio, 
pp. 903-913. 
Männistö, PT, Tuominen, RK 2007, 'Alkueläimiin vaikuttavat lääkeaineet', Farmakologia ja toksikologia, Medicina, Kuopio, pp. 915-
927. 
Männistö, PT, Tuominen, RK, Tuominen, R 2007, 'Solunseinämää heikentävät bakteerilääkkeet', Farmakologia ja toksikologia, 
Medicina, Kuopio, pp. 823-842. 
Männistö, PT, Tuominen, RK 2007, 'Yleistä mikrobilääkkeistä', Farmakologia ja toksikologia, Medicina, Kuopio, pp. 809-822. 
Raasmaja, AI, Männistö, P 2007, 'Aivolisäkehormonit ja niiden johdokset', Farmakologia ja toksikologia, Medicina, Kuopio. 
Raasmaja, A, Männistö, PT 2007, 'Kilpirauhashormonit ja tyreostaatit', Farmakologia ja toksikologia, Medicina, Kuopio, pp. 679-685. 
Raasmaja, A, Männistö, PT 2007, 'Aivolisäkkeen ja hypotalamuksen hormonit', Farmakologia ja toksikologia, Medicina, Kuopio, pp. 
667-678. 
Raasmaja, A, Männistö, PT 2007, 'Antiseptit ja desinfektioaineet', Farmakologia ja toksikologia, Medicina, Kuopio, pp. 937-948. 
Tuominen, RK 2007, 'Bakteeri-infektioiden rationaalinen hoito', Farmakologia ja toksikologia, Medicina, Kuopio, pp. 875-882. 
Tuominen, RK, Männistö, PT 2007, 'Nukleiinihappoihin vaikuttavat mikrobilääkkeet', Farmakologia ja toksikologia, Medicina, Kuopio, 
pp. 863-874. 
Tuominen, RK 2007, 'Tuberkuloosilääkkeet ja sulfonit', Farmakologia ja toksikologia, Medicina, Kuopio, pp. 883-890. 
Tuominen, RK, Männistö, PT 2007, 'Sieni-infektioiden hoitoon tarkoitetut lääkeaineet', Farmakologia ja toksikologia, Medicina, 
Kuopio, pp. 891-902. 
Tuominen, RK 2007, 'Lisämunuaisen kuorikerroshormonit', Farmakologia ja toksikologia, Medicina, Kuopio, pp. 687-699. 
Tuominen, RK, Männistö, PT 2007, 'Proteiinisynteesiä estävät mikrobilääkkeet', Farmakologia ja toksikologia, Medicina, Kuopio, pp. 
843-862. 
2009 
Collins, A, Salminen, O, Marks, M, Whiteaker, P, Grady, S 2009, 'The road to discovery of neuronal nicotinic cholinergic receptor 
subtypes', in JEHEDLSPE;CDA.[A (ed.), Nicotine psychopharmacology, Handbook of experimental pharmacology, Springer, 
cop., Berlin, pp. 85-112. 
A4 Article in conference publication (refereed) 
2007 
Uutela, PS, Karhu, L, Piepponen, TP, Ketola, R, Kostiainen, R 2007, 'Discovery of Dopamine Glucuronide in Brain, Using Liquid 
Chromatography-Tandem Mass Spectrometry', in the 55th ASMS Conference on Mass Spectrometry and Allied Topics,. 
2008 
Hanzlikova, M, Galli, E, Urtti, A, Raasmaja, A, Ruponen, M, Yliperttula, M 2008, The role of free polyethylene imine (PEI) in gene 
delivery by DNA-PEI complexes,, Human Gene Therapy 19 MARY ANN/LIEBERT, INC. PUBLISHERS. 
B1 Unrefereed journal article 
2005 
Hirvonen, J, Raasmaja, A, Tuominen, R 2005, 'Farmasian tutkijakoulutapaaminen 2005', Dosis, vol 21, no. 3, pp. 206. 
Raasmaja, A 2005, 'Testing an interactive lecturing technique for teaching',  Learning technology. 
Tuominen, R, Raasmaja, A (eds) 2005, 'Graduate School Joint Meeting in Pharmaceutical Sciences 2005',  Dosis, vol 21, no. 3, pp. 
207-232. 
2006 
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Männistö, P, Raasmaja, A 2006, 'Farmasian tutkijakoulun tapaaminen Kuopiossa 17.-18.8.2006', Dosis, vol 2006/22, no. 4, pp. 347-
388. 
Tuominen, RK 2006, 'Protein kinases as drug targets', Dosis, vol 22, no. 2, pp. 88-92. 
Yli-Kauhaluoma, J, Sivonen, K, Tuominen, RK 2006, 'Protein kinase research in the University of Helsinki', Dosis, vol 22, no. 2, pp. 152-
7. 
2007 
Männistö, PT, Reenilä, I 2007, 'Joint meeting of FinPharmaNet graduate schools in August 15-16, 2007, in the University of Helsinki', 
Dosis, vol 23, no. 3, pp. 222-224. 
Männistö, PT, Reenilä, I 2007, 'FinPharmaNet-tutkijakoulutapaaminen Helsingin yliopistossa 15.-16. elokuuta 2007', Dosis, vol 23, no. 
3, pp. 221. 
2008 
Reenilä, I, Scheinin, M 2008, 'Joint meeting of FinPharmaNet graduate schools, august 21.-22. 2008, University of Turku', Dosis, vol 
24, no. 3, pp. 231-232. 
Reenilä, I, Scheinin, M 2008, 'FinPharmaNet-tutkijakoulutapaaminen Turun yliopistossa 21.-22. elokuuta 2008',  Dosis, vol 24, no. 3, pp. 
230-231. 
2009 
Reenilä, I, Neuvonen, P 2009, 'FinPharmaNet-verkoston tutkijakoulutapaaminen Helsingin yliopistossa 13.-14.8.2009', Dosis, vol 25, 
no. 3, pp. 144. 
Reenilä, I, Neuvonen, P 2009, 'Joint Meeting of the FinPharmaNet graduate schools, August 13-14, University of Helsinki',  Dosis, vol 
25, no. 3, pp. 145. 
B3 Unrefereed article in conference proceedings 
2008 
Tenorio-Laranga, J, Männistö, PT, Garcia Horsman, JA 2008, In search of physiological substrates of brain prolyl oligopeptidase,, 
Paper presented at European Peptide Symposium (30EPS), Helsinki, Finland. 31. August - 05. September, 2008. Journal of Peptide 
Science 14 S1 JOHN/WILEY & SONS LTD.. 
Venäläinen, J, Garcia-Horsman, A, Piltonen, M, Mannisto, P, Myohanen, T 2008, Distribution of prolyl oligopeptidase in the mouse 
wholebody sections and peripheral tissues,, Paper presented at European Peptide Symposium (30EPS), Helsinki , Finland. 31. 
August - 05. September, 2008. Journal of Peptide Science 14 S1 JOHN/WILEY & SONS LTD.. 
D1 Article in professional journal 
2010 
Reenilä, I, Vähäkangas, K 2010, 'Joint meeting of the FinPharmaNet graduate schools, August 30 – 31 2010, University of Tampere', 
Dosis, vol 26, no. 3, pp. 181. 
Reenilä, I, Vähäkangas, K 2010, 'FinPharmaNet-verkoston tutkijakoulutapaaminen Tampereen yliopistossa 30. – 31. elokuuta 2010', 
Dosis, vol 26, no. 3, pp. 180. 
D3 Article in professional conference proceedings 
2010 
Laivisto, E, Wilhelmson, A, Wilpola, A, Garcia Horsman, JA, Salovaara, H, Loponen, J  2010, 'Hydrolytic potential of malts prepared of 
three rye varieties and impact on prolamin breakdown during acidification', in GF10 Second International Symposium of Gluten-free 
Cereal Products and Beverages: book of abstracts, pp. 83-84. 
D4 Published development or research report 
2009 
Tuominen, R 2009, Developing drug desing through protein kinases, Insight Publishers, Bristol, UK. 
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E1 Popular article, newspaper article 
2005 
Heinimo, S, Lehtonen, U, Säkkinen, M, Raasmaja, A 2005, 'Vuorovaikutteinen opetus äänestysjärjestelmää käyttäen', Peda-Forum, vol 
12, no. 2, pp. 7-9. 
Pakkanen, J 2005, 'Verisuonitukosten aiheuttamat infarktit ovat ehkäistävissä lääkehoidolla', Apteekkari : Suomen apteekkarilehti, vol 
2005, no. 7, pp. 18-19. 
Talman, V 2005, 'Nivelreuman hoidossa monia mullistuksia', Apteekkari : Suomen apteekkarilehti, vol 2005, no. 5, pp. 28-29. 
2008 
Tuominen, RK, Gordin, A 2008, 'Ovatko hermokasvutekijät tulevaisuuden Parkinson-lääkkeitä?', Parkinson-postia, vol 21, no. 5, pp. 
36. 
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1 Analysis of activities 2005-2010 
 
- Associated person is one of Pekka Männistö ,  Raimo Tuominen ,  Timo Petteri Piepponen , 
 Atso Raasmaja , Outi Salminen ,  Tanja Kivinummi ,  
Elina Ekokoski ,  Juan Arturo Garcia Horsman ,  Timo Tapio Myöhänen ,  Ilkka Reenilä , 
 Mikko Airavaara ,  Sanna Janhunen, Jelena Mijatovic ,  Jukka Pakkanen , 
 Anne Emilia Tammimäki ,  Jofre Tenorio-Laranga ,  Susanne Bäck , 
 ,  Oleg Kambur ,  Jaakko Kopra ,  Mikko Käenmäki , 
 Bernardino Ossola ,  Iida Peltonen ,  Marjo Hannele Piltonen , 
 Lauriina Porokuokka , Nadia Schendzielorz ,  Reeta Talka , 
 Virpi Talman , Merja Voutilainen ,  
 
Activity type Count 
Supervisor or co-supervisor of doctoral thesis 39 
Prizes and awards 4 
Editor of research journal 31 
Peer review of manuscripts 52 
Editor of special theme number 2 
Assessment of candidates for academic posts 3 
Membership or other role in review committee 3 
Membership or other role in research network 3 
Membership or other role in national/international committee, council, board 25 
Membership or other role in public Finnish or international organization 22 
Membership or other role of body in private company/organisation 10 
Other tasks of an expert in private sector 3 
Participation in interview for written media 24 
Participation in radio programme 1 
Participation in TV programme 1 
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2 Listing of activities 2005-2010 
Supervisor or co-supervisor of doctoral thesis 
Pekka Männistö ,  
Supervision of Ph.D. Thesis project (Jarkko Venäläinen), Pekka Männistö, 01.04.2005  31.12.2005, Finland 
Supervision of Ph.D. Thesis project (Sarka Manakova), Pekka Männistö, 15.04.2005  31.12.2005, Finland 
Supervisor of Ph.D. Thesis project (Katja Puttonen), Pekka Männistö, 2005  … 
Supervisor of Ph.D. Thesis project (Markus Forsberg), Pekka Männistö, 2005  …, Finland 
Supervisor of Ph.D. Thesis project (Bernardino Ossola), Pekka Männistö, 2006  …, Italy 
Supervisor of Ph.D. Thesis project (Marjo Piltonen), Pekka Männistö, 2006  …, Finland 
Supervisor of Ph.D. Thesis project (Aaro Jalkanen), Pekka Männistö, 2007  … 
Supervisor of Ph.D. Thesis project (Iida Peltonen), Pekka Männistö, 2007  …, Finland 
Supervisor of Ph.D. Thesis project (Nadia Schendzielorz), Pekka Männistö, 2007  …, Germany 
Supervisor of Ph.D. Thesis project (Oleg Kambur), Pekka Männistö, 2007  …, Finland 
Supervision of Ph.D. Thesis project (Kati Mönkkönen), Pekka Männistö, 11.04.2008  31.12.2008, Finland 
Supervision of Ph.D. Thesis project (Tiina Kääriäinen), Pekka Männistö, 13.12.2008  31.12.2008, Finland 
Supervision of Ph.D. Thesis project (Timo Myöhänen), Pekka Männistö, 06.06.2008  31.12.2008, Finland 
Supervisor of Ph.D. Thesis project (Mikko Käenmäki), Pekka Männistö, 2008  … 
Supervisor of Ph.D. Thesis project (Susanne Bäck), Pekka Männistö, 2009  … 
Raimo Tuominen ,  
Supervisor of doctoral studies by Virpi Talman: Pharmacological characterization of novel compounds targeted to the C1 domain of 
protein kinase C, Raimo Tuominen, 2004  …, Finland 
Supervisor of doctoral thesis by Sanna Janhunen, University of Helsinki: Different responses of the nigrostriatal and mesolimbic 
dopaminergic pathways to nicotinic receptor agonists, Raimo Tuominen, 06.2005, Finland 
Supervisor of doctoral thesis by Jukka S. Pakkanen, University of Helsinki: Upregulation and functionality of neuronal nicotinic 
acetylcholine receptors, Raimo Tuominen, 28.04.2006, Finland 
Supervisor of doctoral thesis by Tomi Rantamäki, University of Helsinki: Brain TrkB neurotrophin receptor as a target for antidepressant 
treatments, Raimo Tuominen, 28.10.2006, Finland 
Supervisor of doctoral studies by Milla Paalanen: Llama heavy chain antibodies (VHHs) as activators and inhibitors of PKC epsilon, 
Raimo Tuominen, 2007  …, Netherlands 
Supervisor of doctoral studies by Reeta Talka: Nicotine opioid interactions at cellular level, Raimo Tuominen, 2007  …, Finland 
Supervisor of doctoral studies by Susanne Bäck: Novel neurotrophic factors in experimental rat models of Parkinson's diesease, Raimo 
Tuominen, 2007  …, Finland 
Supervisor of doctoral thesis by Saara Nuutinen, University of Helsinki; The effects of nicotine on the regulation of neuronal alpha7 
nicotinic acetylcholine receptors and intracellular signaling pathways, Raimo Tuominen, 10.03.2007, Finland 
Supervisor of doctoral thesis by Tanja Kivinummi (nee Vihavainen), University of Helsinki: Effects of chronic nicotine on behavioural and 
neurochemical responses to morphine, Raimo Tuominen, 06.02.2009, Finland 
Supervisor of doctoral thesis by Merja H. Voutilainen, University of Helsinki: CDNF and MANF in an experimental model of Parkinson’s 
disease in rats, Raimo Tuominen, 18.12.2010, Finland 
Supervisor of doctoral thesis by Tiina M. Leppänen, University of Tampere, Finland: Protein kinase C in the Regulation of Inflammatory 
Genes iNOS and TTP, Raimo Tuominen, 20.08.2010, Finland 
Timo Petteri Piepponen ,  
Supervision of the Ph.D. thesis of Mikko Airavaara, Timo Petteri Piepponen, 2001  2006, Finland 
Supervision of the Ph.D. thesis of Kristiina Kaste, Timo Petteri Piepponen, 2002  2009, Finland 
Supervision of the Ph.D. thesis of Jelena Mijatovic, Timo Petteri Piepponen, 2004  2009, Finland 
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Atso Raasmaja ,  
Supervision of doctoral thesis of Martina Hanzlikova, Atso Raasmaja, 01.09.2004  … 
Supervision of doctoral thesis of Bernardino Ossola, Atso Raasmaja, 01.01.2006  … 
Supervision of doctoral thesis of Nadia Schendzielorz, Atso Raasmaja, 01.01.2006  … 
Supervision of doctoral thesis of Tiina Lantto, Atso Raasmaja, 01.01.2007  … 
Supervision of doctoral thesis of Susanne Bäck, Atso Raasmaja, 01.01.2008  … 
Supervisor of doctoral thesis by Tanja Kivinummi, Atso Raasmaja, 02.06.2009 
Supervisor of doctoral thesis by Merja Voutilainen, Atso Raasmaja, 18.12.2010 
Juan Arturo Garcia Horsman ,  
Doctoral Thesis Supervisor Maria José Moreno Baylach, Juan Arturo Garcia Horsman, 2004  2010, Spain 
Doctoral Thesis Supervisor, Jofre Tenorio Laranga, Juan Arturo Garcia Horsman, 2009, Spain 
Ilkka Reenilä ,  
Väitöskirjan ohjaus, Ilkka Reenilä, 2007  … 
Prizes and awards 
Pekka Männistö ,  
Honorary Doctor of Tartu University, Estonia, Pekka Männistö, 2010  …, Estonia 
Honorary Member of Estonian Pharmacological Society, Pekka Männistö, 30.11.2010  …, Estonia 
Timo Petteri Piepponen ,  
The Orion Pharma Recognition Prize, Timo Petteri Piepponen, 04.04.2008, Finland 
Juan Arturo Garcia Horsman ,  
Ramón y Cajal Fellow, Juan Arturo Garcia Horsman, 2004  2008 
Editor of research journal 
Pekka Männistö ,  
European Journal of Pharmaceutical Sciences, section editor, Pekka Männistö, 01.01.2006  31.12.2006 
European Journal of Pharmacology, Pekka Männistö, 01.01.2006  31.12.2006 
Pharmacogenetics, Pekka Männistö, 01.01.2006  31.12.2006 
Editor of Open Enzyme Inhibition Journal, Pekka Männistö, 2007  … 
European Journal of Pharmaceutical Sciences, section editor, Pekka Männistö, 01.01.2007  31.12.2007 
Section editor of European Journal of Pharmaceutical Science, Pekka Männistö, 2007  2009 
European Journal of Pharmaceutical Sciences, section editor, Pekka Männistö, 01.01.2008  31.12.2008 
Journal of Enzyme Inhibition, Pekka Männistö, 01.01.2008  31.12.2008 
Raimo Tuominen ,  
Duodecim, Raimo Tuominen, 01.01.2005  31.12.2005, Finland 
European Journal of Pharmaceutical Sciences, Raimo Tuominen, 01.01.2005  31.12.2005, Sweden 
Human and Experimental Toxicology, Raimo Tuominen, 01.01.2005  31.12.2005, United Kingdom 
Duodecim, Raimo Tuominen, 01.01.2006  31.12.2006, Finland 
European Journal of Pharmaceutical Sciences, Raimo Tuominen, 01.01.2006  31.12.2006, Sweden 
Synapse, Raimo Tuominen, 01.01.2006  31.12.2006, United States 
Basic &amp; Clinical Pharmacology and Toxicology, Raimo Tuominen, 01.06.2007  31.12.2007, Denmark 
Behavioural Brain Research, Raimo Tuominen, 01.09.2007  30.09.2007, Netherlands 
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European Journal of Pharmaceutical Sciences, Raimo Tuominen, 01.05.2007  30.11.2007, Sweden 
Pharmacological Research, Raimo Tuominen, 01.08.2007  31.08.2007, Italy 
Basic &amp; Clinical Pharmacology and Toxicology, Raimo Tuominen, 01.03.2008  31.03.2008, Denmark 
Brain Research, Raimo Tuominen, 01.08.2008  31.08.2008, Netherlands 
Current Pharmaceutical Design, Raimo Tuominen, 01.10.2008  31.10.2008, Netherlands 
European Journal of Endocrinology, Raimo Tuominen, 01.03.2008  30.11.2008, United Kingdom 
European Journal of Pharmaceutical Sciences, Raimo Tuominen, 01.03.2008  30.11.2008, Sweden 
Pharmacological Research, Raimo Tuominen, 01.01.2008  31.12.2008, Italy 
Timo Petteri Piepponen ,  
Dosis, Timo Petteri Piepponen, 27.10.2005  31.12.2005, Finland 
Talanta, Timo Petteri Piepponen, 04.07.2005  31.12.2005, Netherlands 
European Journal of Pharmaceutical Sciences, Timo Petteri Piepponen, 19.10.2006  31.12.2006, Netherlands 
Pharmacology Biochemistry and Behavior, Timo Petteri Piepponen, 13.11.2006  31.12.2006, Netherlands 
European Journal of Pharmaceutical Sciences, Timo Petteri Piepponen, 28.03.2007  31.12.2007, Netherlands 
Juan Arturo Garcia Horsman ,  
Frontiers in Aging Neuroscience, Review Editor, Juan Arturo Garcia Horsman, 2009  2010, United Kingdom 
Anne Emilia Tammimäki ,  
European Journal of Pharmaceutical Sciences, Anne Emilia Tammimäki, 01.01.2008  31.12.2008 
Peer review of manuscripts 
Pekka Männistö ,  
Brain Research, Pekka Männistö, 01.01.2005  31.12.2005 
European Journal of Pharmaceutical Sciences, Pekka Männistö, 01.01.2005  31.12.2005 
European Journal of Pharmacology, Pekka Männistö, 01.01.2005  31.12.2005 
Life Sciences, Pekka Männistö, 01.01.2005  31.12.2005 
Referee of 9 scientific journals, Pekka Männistö, 2005  2010 
Brain Research, Pekka Männistö, 01.01.2006  31.12.2006 
European Journal of Pharmaceutical Sciences, Pekka Männistö, 01.01.2006  31.12.2006 
Life Sciences, Pekka Männistö, 01.01.2006  31.12.2006 
Behavioral Brain Research, Pekka Männistö, 01.01.2007  31.12.2007 
Biochemistry Behavior &amp; Pharmacology, Pekka Männistö, 01.01.2007  31.12.2007 
Brain Research, Pekka Männistö, 01.01.2007  31.12.2007 
European Journal of Pharmaceutical Sciences, Pekka Männistö, 01.01.2007  31.12.2007 
European Journal of Pharmacology, Pekka Männistö, 01.01.2007  31.12.2007 
Pharmacogenetics, Pekka Männistö, 01.01.2007  31.12.2007 
Behavioral Brain Research, Pekka Männistö, 01.01.2008  31.12.2008 
Biochemistry Behavior &amp; Pharmacology, Pekka Männistö, 01.01.2008  31.12.2008 
Brain Research, Pekka Männistö, 01.01.2008  31.12.2008 
European Journal of Pharmacology, Pekka Männistö, 01.01.2008  31.12.2008 
Pharmacogenetics, Pekka Männistö, 01.01.2008  31.12.2008 
Pharmacogenomics, Pekka Männistö, 01.01.2008  31.12.2008 
Raimo Tuominen ,  
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Peer Review Duodecim Medical Publications, Raimo Tuominen, 02.02.2010, Finland 
Peer Review International Journal of Molecular Sciences, Raimo Tuominen, 10.10.2010, Switzerland 
Timo Petteri Piepponen ,  
Referee of 6 scientific journals, Timo Petteri Piepponen, 01.01.2005  31.12.2010 
Journal of Chromatography B, Timo Petteri Piepponen, 17.03.2006  31.12.2006, Netherlands 
Biomedical Chromatography, Timo Petteri Piepponen, 13.07.2008  31.12.2008, United States 
European Journal of Pharmaceutical Sciences, Timo Petteri Piepponen, 28.10.2008  31.12.2008, Netherlands 
Atso Raasmaja ,  
Peer review of Journal of Enzyme Inhibition, Atso Raasmaja, 01.01.1998  … 
Peer review of Biomaterials, Atso Raasmaja, 01.01.2004  … 
Peer review of Journal of Human &amp; Environmental Toxicology, Atso Raasmaja, 01.01.2004  … 
Peer review of European Journal of Pharmaceutical Sciences, Atso Raasmaja, 01.01.2006  … 
Peer Review of Current Drug Safety, Atso Raasmaja, 01.01.2007  … 
Peer Review of Food Chemistry, Atso Raasmaja, 01.01.2009  … 
Peer Review of Acta Biomaterialia, Atso Raasmaja, 01.01.2010  … 
Outi Salminen ,  
Basic &amp; Clinical Pharmacology &amp; Toxicology, Outi Salminen, 01.09.2006  30.11.2006 
Neuroscience, Outi Salminen, 01.08.2006  30.08.2006, United States 
The Journal of Physiological Sciences, Outi Salminen, 01.10.2006  31.10.2006, Japan 
Neuroscience, Outi Salminen, 01.09.2007  30.09.2007, United States 
Neuroscience Letters, Outi Salminen, 01.04.2008  30.04.2008, United States 
Käsikirjoituksen vertaisarviointi, Outi Salminen, 27.04.2010 
Käsikirjoituksen vertaisarviointi, Outi Salminen, 2010 
Juan Arturo Garcia Horsman ,  
BBA-Proteins and Proteomics, Reviewer, Juan Arturo Garcia Horsman, 10.2007  2011 
Biochemical Pharmacology, Reviewer, Juan Arturo Garcia Horsman, 2007  … 
Toxicology Letters, Reviewer, Juan Arturo Garcia Horsman, 2007  … 
ChemMedChem, Reviewer, Juan Arturo Garcia Horsman, 2008  … 
Gene, Reviewer, Juan Arturo Garcia Horsman, 2008  … 
Aging Cell, Reviewer, Juan Arturo Garcia Horsman, 2009  … 
European Journal of Pharmaceutical Sciences, Reviewer, Juan Arturo Garcia Horsman, 2009  … 
FEBS Letters, Reviewer, Juan Arturo Garcia Horsman, 03.2009  04.2009 
Expert Opinion on Therapeutic Patents, Reviewer, Juan Arturo Garcia Horsman, 2010  … 
Timo Tapio Myöhänen ,  
Brain Research, Timo Tapio Myöhänen, 2009 
CNS &amp; Neurological Disorders – Drug Targets, Timo Tapio Myöhänen, 2010 
Regulatory Peptides, Timo Tapio Myöhänen, 2010 
Editor of special theme number 
Raimo Tuominen ,  
Co Quest-editor Current Topics in Medicinal Chemistry, Raimo Tuominen, 2010  …, Switzerland 
Juan Arturo Garcia Horsman ,  
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Special Issue Editor CNS Neurological Disorders - Drug Targets, Juan Arturo Garcia Horsman, 05.2010  04.2011, United Kingdom 
Assessment of candidates for academic posts 
Pekka Männistö ,  
Evaluator of Professorship, Pekka Männistö, 2010  … 
Raimo Tuominen ,  
Assesment of professor of Physiological Genomics, University of Tartu, Tartu, Estonia, Dr. Sulev Kõks, MD, PhD, Raimo Tuominen, 
2008, Estonia 
Steering Group for Tenure Track position in Faculty of Pharmacy, Raimo Tuominen, 01.08.2010  …, Finland 
Membership or other role in review committee 
Raimo Tuominen ,  
Grant Review Wellcome Trust, Raimo Tuominen, 09.09.2010, United Kingdom 
Grant Review, Instrumentarium Science Foundation, Raimo Tuominen, 30.11.2010, Finland 
Grant review Helsinki University Research Council, Raimo Tuominen, 06.06.2010, Finland 
Membership or other role in research network 
Atso Raasmaja ,  
Finnish Society for Pharmacology (Suomen Farmakologiyhdistys), Atso Raasmaja, 01.01.1996  … 
Finnish Society for Gene Therapy (Suomen Geeniterapiayhdistys), Atso Raasmaja, 01.01.1998  … 
Juan Arturo Garcia Horsman ,  
Member of Viikki Research Group Organization, Juan Arturo Garcia Horsman, 2010  …, Finland 
Membership or other role in national/international committee, council, board 
Pekka Männistö ,  
Doctoral Dissertation Supervisor in Kuopio University (3 times in 2005, 3 times in 2008), Pekka Männistö, 2005  2008 
Evaluator of a Wellcome Trust grant, Pekka Männistö, 01.01.2006  31.12.2006 
Evaluation Board of the Strategic Funds of Norway Research Council, Pekka Männistö, 20.05.2009  …, Norway 
Evaluator of Welcom Trust Funds, Pekka Männistö, 2009  …, United Kingdom 
Evaluator of the Millenium Price candidates, Pekka Männistö, 2009  … 
Board member or vice member of 5 Helsinki University bodies, Pekka Männistö, 2010  …, Finland 
Evaluation of Docentship (Mikko Unkila), Pekka Männistö, 2010  … 
Evaluator of the British Medical Research Council (MRC), Pekka Männistö, 2010  … 
Raimo Tuominen ,  
Pharmacology Expert in Pharmaca Fennica, the Finnish Physicians Desk Reference, Raimo Tuominen, 01.01.2000  31.12.2010 
Memeber of the Board, Biocentrum Helsinki, University of Helsinki, Finland, Raimo Tuominen, 01.01.2002  31.12.2010, Finland 
Head of the Graduate School of Pharmaceutical Siences, Raimo Tuominen, 01.01.2004  31.12.2005, Finland 
Grant Review, Wellcome Trust, Raimo Tuominen, 28.02.2006  31.12.2006, United Kingdom 
Grant reviewer for Instrumentarium Science Foundation, Helsinki, Finland, Raimo Tuominen, 01.12.2008  31.12.2010, Finland 
Viikki Campus research ethics committee, Raimo Tuominen, 01.01.2010  31.12.2010, Finland 
Timo Petteri Piepponen ,  
Lääketutkimussäätiö, Timo Petteri Piepponen, 01.01.2007  31.12.2007, Finland 
Suomen farmakologiyhdistys (Finnish Pharmacological Society), Timo Petteri Piepponen, 01.01.2007  31.12.2007, Finland 
Lääketutkimussäätiö, Timo Petteri Piepponen, 01.01.2008  31.12.2008, Finland 
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Suomen farmakologiyhdistys (Finnish Pharmacological Society), Timo Petteri Piepponen, 01.01.2008  31.12.2008, Finland 
Atso Raasmaja ,  
Expert, Atso Raasmaja, 01.12.2008  … 
Outi Salminen ,  
Suomen Apteekkariliiton Savuttomuustyöryhmä, Outi Salminen, 2008  …, Finland 
Neurotieteen tutkimuskeskuksen johtokunnan varajäsen, Outi Salminen, 2010  …, Finland 
Juan Arturo Garcia Horsman ,  
Chair of the board of NEUROPRO cosortium, Juan Arturo Garcia Horsman, 01.10.2008  30.09.2012 
Evaluator of Parkinson's UK, Juan Arturo Garcia Horsman, 2010, United Kingdom 
FP7 Expert Evaluator, Juan Arturo Garcia Horsman, 2010  2012, Belgium 
Mikko Airavaara ,  
Helsingin yliopiston farmasian tiedekunnan tutkimusasiaintoimikunta, Mikko Airavaara, 01.01.2002  31.12.2005 
Membership or other role in public Finnish or international organization 
Raimo Tuominen ,  
Lääkelaitos, Nikotiinikorvaushoitoon tarkoitettujen valmisteiden myynti vähittäiskaupoissa, Raimo Tuominen, 12.05.2005  31.12.2005, 
Finland 
Lääkelaitos, Quality Audit of Non-Clinical and Clinical Assessment Report, Raimo Tuominen, 01.03.2005  31.03.2005, Finland 
Kliiiniset lääketutkimukset seminaarin järjestelytoimikunta, Raimo Tuominen, 10.05.2006  11.05.2006, Finland 
Lausunto uudesta lääkaineesta Orion-Pharmalle, Raimo Tuominen, 22.09.2006  31.12.2006, Finland 
Lausunto uudesta lääkeaineesta Lääkelaitokselle, Raimo Tuominen, 28.06.2006  31.12.2006, Finland 
Lääketietokeskus Oy, Rekisteröity lääke-esittelijä koulutus, Raimo Tuominen, 01.01.2006  31.12.2006, Finland 
Lääkelaitos, Raimo Tuominen, 01.05.2007  31.10.2007, Finland 
Lääkelaitos, Raimo Tuominen, 01.05.2008  31.10.2008, Finland 
Member of Board, Raimo Tuominen, 01.08.2010  31.12.2010, Finland 
Atso Raasmaja ,  
Coordinator of the Pharmacy Research School, Atso Raasmaja, 01.01.2004  31.12.2006 
Chair of Committee for Student Qualification, Atso Raasmaja, 01.01.2005  31.12.2006 
Deputy member of Collegial Body, Atso Raasmaja, 31.01.2010  … 
Member of Teaching Skill Committee, Atso Raasmaja, 01.01.2010  … 
Outi Salminen ,  
Suomen Apteekkariliiton Savuttomuustoimikunts (SALSA), Outi Salminen, 01.01.2008  31.12.2008, Finland 
Farmasian tdk:n opintoasiain toimikunnan jäsen, Outi Salminen, 2010  …, Finland 
Farmasian tdk:n tiedekuntaneuvoston varajäsen, Outi Salminen, 2010  …, Finland 
Ilkka Reenilä ,  
Suomen farmakologiyhdistys (Finnish Pharmacological Society), member, Ilkka Reenilä, 1991  …, Finland 
Suomen aivotutkimussäätiö (Brain Research Society of Finland), member, Ilkka Reenilä, 2003  …, Finland 
Chairperson of Quality assurance group / Division of Pharmacology and Toxicology, University of Helsinki, Ilkka Reenilä, 2007  … 
Member of Quality assurance group / University of Helsinki, Ilkka Reenilä, 2007  … 
Mikko Käenmäki ,  
Farenta oy, Mikko Käenmäki, 01.10.2007  31.10.2007, Finland 
Farenta oy, Mikko Käenmäki, 01.01.2008  31.12.2008, Finland 
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Membership or other role of body in private company/organisation 
Pekka Männistö ,  
Board Member of Finnish Pharmacological Society (Suomen Farmakologiyhdistys), Pekka Männistö, 01.01.2005  31.12.2005, Finland 
Member of board of directors (Cerebricon Ltd), Pekka Männistö, 2007  2009, Finland 
Member of board of directors (Hermopharma Ltd.), Pekka Männistö, 2010  …, Finland 
Ilkka Reenilä ,  
Authorized representative, secretary / Society for Drug Research, Ilkka Reenilä, 2005  …, Finland 
Lääketutkimussäätiö, Ilkka Reenilä, 2005  …, Finland 
Mikko Käenmäki ,  
Yliopiston farmasiakunta, talousvaliokunta, Mikko Käenmäki, 01.01.2005  31.12.2005 
Yliopiston farmasiakunta, talousvaliokunta, Mikko Käenmäki, 01.01.2006  31.12.2006 
Yliopiston farmasiakunta, talousvaliokunta, Mikko Käenmäki, 01.01.2007  31.12.2007, Finland 
Yliopiston farmasiakunta, talousvaliokunta, Mikko Käenmäki, 01.01.2008  31.12.2008, Finland 
Marjo Hannele Piltonen ,  
Farmasian opettajien ja tutkijoiden yhdistys, Marjo Hannele Piltonen, 01.01.2007  31.12.2007, Sweden 
Other tasks of an expert in private sector 
Raimo Tuominen ,  
Pharmacology Expert, Raimo Tuominen, 01.01.2000  31.12.2010, Finland 
Lectures in Pharmacology, Raimo Tuominen, 01.01.2010  31.12.2010, Finland 
Mikko Käenmäki ,  
Farmakologian asiantuntija, Mikko Käenmäki, 01.08.2007  … 
Participation in interview for written media 
Pekka Männistö ,  
Interview for a newspaper (Haastattelut, joiden perusteella lehtiartikkeli), Savon Sanomat, Pekka Männistö, 01.01.2007  31.12.2011, 
Finland 
Interview for a periodical (Haastattelut, joiden perusteella lehtiartikkeli), Resepti, Pekka Männistö, 01.01.2007  31.12.2011, Finland 
Raimo Tuominen ,  
Terveys ja Kauneus 2003, Raimo Tuominen, 15.11.2003  31.12.2011, Finland 
Tieteen päivät, Raimo Tuominen, 11.01.2003  31.12.2011, Finland 
Mediuutiset nro 14 (Farmasian eripainos), Raimo Tuominen, 01.01.2004  31.12.2011, Finland 
Tiede tunnetuksi tarinoita kansainvälisestä tutkimuksesta, Taideteollinen korkeakoulu, Helsinki, Raimo Tuominen, 16.11.2004  
31.12.2011, Finland 
Forum Pharmaceuticum - Pharmaca Fennica 30 vuotta, Raimo Tuominen, 06.10.2005, Finland 
Kliiniset lääketutkimukset, Raimo Tuominen, 06.04.2005  31.12.2011, Finland 
Lääketietokeskuksen julkaisu, Raimo Tuominen, 12.09.2005  31.12.2011, Finland 
Raportointi ja tilintarkastukset puiteohjelma-hankkeissa., Raimo Tuominen, 17.02.2005  31.12.2011, Finland 
Chairman of a symposium, Raimo Tuominen, 18.11.2007, Finland 
Kliiniset Lääketutkimukset seminaari, Raimo Tuominen, 26.04.2007  31.12.2011, Finland 
Lehti; Resepti (ALMA media), Raimo Tuominen, 01.03.2007  31.12.2011, Finland 
Suomen Kuvalehti 27/2007, Raimo Tuominen, 01.07.2007  31.12.2011, Finland 
Farmasian päivät 2008, Raimo Tuominen, 16.11.2008  31.12.2011, Finland 
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Kliiniset Lääketutkimukset seminaari, Raimo Tuominen, 09.04.2008  31.12.2011, Finland 
Timo Petteri Piepponen ,  
Farmasian päivät, Timo Petteri Piepponen, 16.11.2001  31.12.2011, United States 
Viikki-päivä, Timo Petteri Piepponen, 06.10.2005  31.12.2011, Finland 
Outi Salminen ,  
Kätilöliiton koulutuspäivä ”Edessä hyvä elämä”, Outi Salminen, 20.10.2006, Finland 
Tupakka ja terveys-päivä, Outi Salminen, 12.12.2006, Finland 
Mikko Airavaara ,  
Suomen Apteekkarilehti 5:28-29, Mikko Airavaara, 01.01.2003  …, Finland 
Jukka Pakkanen ,  
Apteekkari-lehti 07/05, Jukka Pakkanen, 01.01.2005  31.12.2011, Spain 
Anne Emilia Tammimäki ,  
Farmasian päivät, Anne Emilia Tammimäki, 18.11.2001  31.12.2011, France 
Virpi Talman ,  
Apteekkari-lehti 5/2005, Virpi Talman, 01.01.2005  31.12.2011, Finland 
Participation in radio programme 
Raimo Tuominen ,  
Radiohaastattelu ohjelmassa Radiaattori, Raimo Tuominen, 23.08.2006  31.12.2011, Finland 
Participation in TV programme 
Timo Petteri Piepponen ,  
Tutkiva Juttu - jäin koukkuun, Timo Petteri Piepponen, 08.04.2008, Finland 
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Web of Science(WoS)-based bibliometrics of the RC’s publications data 1.1.2005-31.12.2010  
by CWTS, Leiden University, the Netherlands 
Research Group: Tuominen R 
Basic statistics 
Number of publications (P) 111 
Number of citations (TCS) 742 
Number of citations per publication (MCS)   6.69 
Percentage of uncited publications 23% 
Field-normalized number of citations per publication (MNCS)    .94 
Field-normalized average journal impact (MNJS)   1.09 
Field-normalized proportion highly cited publications (top 10%)    .76 
Internal coverage    .92 
 
Trend analyses 
 
MNCS 
 
THCP10 
 
MNJS 
Collaboration 
 
Performance (MNCS) by collaboration type 
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